piperacillin has been researched along with Pseudomonas Infections in 222 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 50 (22.52) | 18.7374 |
| 1990's | 21 (9.46) | 18.2507 |
| 2000's | 58 (26.13) | 29.6817 |
| 2010's | 83 (37.39) | 24.3611 |
| 2020's | 10 (4.50) | 2.80 |
| Authors | Studies |
|---|---|
| Dumas, JL; Köhler, T; Reinhardt, A; Ricou, B; Rohner, P; van Delden, C; Wood, P | 1 |
| Ariza, J; Dominguez, MA; Gudiol, F; Guzmán, A; Peña, C; Pujol, M; Suarez, C; Tubau, F | 1 |
| Bulitta, JB; Drusano, GL; Duffull, SB; Holzgrabe, U; Kinzig-Schippers, M; Sörgel, F; Stephan, U | 1 |
| Cuzon, G; Lartigue, MF; Naas, T; Nordmann, P; Quinn, JP; Villegas, MV | 1 |
| Chen, T; Khalil, H; Riffon, R; Wang, R; Wang, Z | 1 |
| Carrillo, B; Esparza-Ahumada, S; Garza-Ramos, U; Hernández, E; Jones, RN; Morfin-Otero, R; Rodriguez-Noriega, E; Sader, HS; Sanchez, A; Silva-Sanchez, J | 1 |
| Albertí, S; Beceiro, A; Bou, G; Garau, M; Gutiérrez, O; Juan, C; Oliver, A; Pérez, JL | 1 |
| Fujimoto, S; Ike, Y; Okuzumi, K; Tanimoto, K; Tomita, H | 1 |
| Hanson, ND; Schmidtke, AJ | 1 |
| Duljasz, W; Gniadkowski, M; Jebelean, C; Sitter, S; Wojna, A | 1 |
| Gales, AC; Nordmann, P; Picão, RC; Poirel, L | 1 |
| Albertí, S; Juan, C; Mulet, X; Oliver, A; Pérez, JL; Zamorano, L | 1 |
| Bulik, CC; Crandon, JL; Nicolau, DP | 1 |
| Bonnet, R; Casin, I; Doublet, B; Fabre, L; Le Fleche, A; Robin, F; Weill, FX | 1 |
| De Luca, F; Docquier, JD; Ide, L; Nordmann, P; Poirel, L; Rossolini, GM; Verlinde, A | 1 |
| Ge, Y; Juan, C; Oliver, A; Pérez, JL; Zamorano, L | 1 |
| Kotsakis, SD; Legakis, NJ; Miriagou, V; Papagiannitsis, CC; Tzelepi, E; Tzouvelekis, LS | 1 |
| Ge, Y; Juan, C; Moya, B; Oliver, A; Pérez, JL; Zamorano, L | 1 |
| Al Naiemi, N; Debets-Ossenkopp, YJ; Nordmann, P; Poirel, L; Rodríguez-Martínez, JM | 1 |
| Abele-Horn, M; Claus, H; Elias, J; Engelhardt, K; Frosch, M; Joseph, B; Oesterlein, A; Schoen, C; Turnwald, D; Valenza, G | 1 |
| Bertrand, X; Dehecq, B; Hocquet, D; Mariotte, P; Plésiat, P; Talon, D | 1 |
| Bojkovic, J; Dean, CR; Dobler, M; Dzink-Fox, J; Glick, M; Hamann, LG; Kerrigan, J; Lanieri, L; Lenoir, F; Lilly, MD; Liu, E; Lu, Y; McKenney, D; Nunez, J; Osborne, C; Parker, DT; Patnaik, A; Peng, Y; Piizzi, G; Ranjitkar, S; Sprague, ER; Tommasi, R; Wang, B; Wang, H; Wattanasin, S; Xie, L; Yang, X; Yu, D | 1 |
| Ardebili, A; Bagheri, H; Goharrizi, MASB; Hjimohammadi, A; Izanloo, A; Jamali, A; Shahri, FN | 1 |
| Ahari, H; Anvar, SA; Ataee, M; Dehkordi, SMH; Rahimi, E | 1 |
| Harris, PNA; Humphries, RM; Mathers, AJ; Tamma, PD; Wenzler, E | 1 |
| Khan, M; Ma, K; Wan, I; Willcox, MD | 1 |
| Ali, MG; Almoneim, ZA; Kareem, SM | 1 |
| Autmizguine, J; Kassir, N; Lavigne, J; Litalien, C; Théorêt, Y; Thibault, C | 1 |
| Lomovskaya, O; Tsivkovski, R | 1 |
| Hector, E; Hussein, Z; Lipman, S; Reisfeld, S; Stein, M; Tannous, E; Tonna, A | 1 |
| Sivashanmugam, K; Srivastava, P | 1 |
| Conde, IR; de la Fuente Aguado, J; Ferreiro, JLL; García, JP; González, LG; Otero, JÁ; Rivo, AS; Soneira, MF | 1 |
| Borgatta, B; Gattarello, S; Imbiscuso, AT; Larrosa, MN; Lujàn, M; Mazo, CA; Rello, J | 1 |
| Cahan, A; Cohen, MJ; Kleinhendler, E; Moses, AE; Paltiel, O; Strahilevitz, J | 1 |
| Darmalingam, M; Salciccioli, JD; Woodcock, H | 1 |
| Cho, B; Chung, NG; Han, SB; Jeong, DC; Kang, JH; Kim, HS; Kim, SK; Lee, DG; Lee, JW; Park, BK | 1 |
| Beri, K; Shariff, M | 1 |
| Goodlet, KJ; Nailor, MD; Nicolau, DP | 1 |
| Hindler, JA; Humphries, RM; Miller, SA; Wong-Beringer, A | 1 |
| Castanheira, M; Flamm, RK; Pfaller, MA; Shortridge, D | 1 |
| Bergen, PJ; Bulitta, JB; Kirkpatrick, CMJ; Landersdorfer, CB; Lipman, J; McGregor, MJ; Millen, N; Paterson, DL; Roberts, JA; Sime, FB | 1 |
| Lagan, KM; McArdle, CD; McDowell, DA | 1 |
| Arıcı, M; Balcı, C; Hayran, SA; Ünal, S; Uzun, Ö; Yüce, D | 1 |
| Castanheira, M; Duncan, LR; Flamm, RK; Sader, HS | 1 |
| Andukuri, VG; Iguidbashian, JP; Kukrety, S; Parekh, JD | 1 |
| Fujimura, S; Hayakawa, S; Hirano, T; Kawamura, M; Kikuchi, T; Sato, T; Watanabe, A | 1 |
| Hesford, C; Nakhosteen, A; Sayma, M; Tariq, Z; Walters, HR | 1 |
| Li, J; Ma, W; Sun, S; Wang, D; Yu, C | 1 |
| Abdel Fattah, M; Alfaro, IG; Babich, T; Ben Ami, R; Benito, N; Beovic, B; Buhl, M; Cano, A; Cardona, R; Chazan, B; Dickstein, Y; Gibbs, J; Giske, CG; Gonzalez-Barbera, EM; Gozalo-Marguello, M; Grier, S; Haquin, J; Kofteridis, D; Landes, M; Leibovici, L; Macgowan, A; Machuca, I; Maraki, S; Martinez Martinez, L; Mauer, S; McCarthy, K; Morales, I; Mueller-Premru, M; Naucler, P; Nesher, L; Oliver, A; Pagani, L; Paterson, DL; Paul, M; Pulcini, C; Rivera, A; Rodriguez-Bano, J; Ruiz De Gopegui, E; Saje, A; Salavert, M; Tacconelli, E; Valik, JK; Vitrat, V; Weissman, Y; Yahav, D; Yanovskay, A; Zacharioudaki, M; Zaidman-Shimshovitz, A | 1 |
| Dings, RP; Dunn, DL; Haseman, JR; Leslie, DB; Luong, M; Mayo, KH | 1 |
| Abouchahla, W; Courcol, R; Delebarre, M; Delvallée, M; Dessein, R; Kipnis, E; Mazingue, F; Wallet, F | 1 |
| Giamarellos-Bourboulis, EJ; Karagianni, V; Liakou, P; Menenakos, E; Sabracos, L; Spyridaki, A; Tsaganos, T; Tsovolou, EC; Tzepi, IM; Zografos, G | 1 |
| Hashiguchi, R; Komatsu, M; Matsuyama, S; Moronaga, Y; Nagahara, C; Oshiro, Y; Sameshima, I; Takeyama, H; Tottori, N; Yaita, K; Yamaguchi, Y | 1 |
| Beegle, S; Butterfield, JM; Farkas, J; Lodise, TP; Pai, MP; Rosen, J | 1 |
| Felton, TW; Goodwin, J; Gregson, L; Hope, WW; Howard, SJ; Livermore, J; Neely, MN; O'Connor, L; Sharp, A | 1 |
| Ben Khalifa, S; Daiki, M; Fekih Hassen, A | 1 |
| Fukushima, S; Matsumoto, T; Mizuno, Y; Nakamura, I; Sato, A; Tsukimori, A; Yamaguchi, T | 1 |
| Bruchmann, S; Cabot, G; Haussler, S; Juan, C; Moyà, B; Mulet, X; Oliver, A; Zamorano, L | 1 |
| Aghazadeh, M; Hojabri, T; Hojabri, Z; Mahdian, R; Nahaei, MR; Pajand, O; Pirzadeh, T; Rahmati, M | 1 |
| Baek, MS; Bristow, J; Chen, F; Cheng, J; Fujimura, K; Lynch, SV; Panzer, AR; Peng, Z; Singh, G; Sorek, R; Srinivasan, R; Tringe, SG; Weng, L; Wiener-Kronish, JP | 1 |
| Dietrich, KA; Herzinger, T; Ruzicka, T | 1 |
| Boutoille, D; Bretonnière, C; Caillon, J; Desessard, C; Guitton, C; Jacqueline, C; Potel, G | 1 |
| Castanheira, M; Farrell, DJ; Jones, RN; Mills, JC | 1 |
| Cies, JJ; Jain, J; Kuti, JL | 1 |
| Lye, DC; Ng, TM; Tan, SH; Teng, CB | 1 |
| Antonucci, E; Beumier, M; Cristallini, S; de Backer, D; Donadello, K; Jacobs, F; Roberts, JA; Rondelet, B; Scolletta, S; Taccone, FS; Vincent, JL | 1 |
| Bhambhwani, V; Ghosh, B; Goel, N | 1 |
| Hirose, Y; Ishikawa, H; Kamata, K; Kanemoto, K; Shiotani, S; Suzuki, H; Suzuki, M; Tokuda, Y | 1 |
| Amyot, J; Awissi, DK; Beauchamp, A; Fagnan, M; Hébert, E; Lavallée, C; Lavigne, V; Leblanc, M; Lebrun, G; Munoz, DL; Pichette, V; Robitaille, R; Savoie, M; Tétreault, N; Varin, F | 1 |
| Acosta-García, H; Alfaro-Lara, ER; Bautista-Paloma, FJ; Beltrán-García, M; Cotrina-Luque, J; Gil-Navarro, MV; Luque-Márquez, R | 1 |
| Castanheira, M; Farrell, DJ; Flamm, RK; Huband, MD; Jones, RN; Sader, HS | 1 |
| Akiyama, K; Hamaoka, S; Katoh, H; Kinoshita, M; Naito, Y; Sawa, T; Shimizu, M | 1 |
| Ariano, R; Iacovides, H; Nash, J; Weber, Z; Zelenitsky, S | 1 |
| Bergman, SJ; Metzke, ME; Pointer, S; Schmees, PM; Strader, BD; Valenti, KM | 1 |
| Bergen, PJ; Bulitta, JB; Kirkpatrick, CM; Landersdorfer, CB; Lipman, J; McGregor, MJ; Paterson, DL; Roberts, JA; Rogers, KE; Wallis, SC | 1 |
| Higuchi, H; Horikoshi, Y; Isogai, M; Ito, K; Shoji, T; Suwa, J | 1 |
| Choudhary, S; Makwana, M; Soni, JP; Tripathi, N | 1 |
| Becker, K; Bletz, S; Böking, T; Harmsen, D; Kipp, F; Mellmann, A; Prior, K; Schultes, A | 1 |
| Bhanot, N; Makadia, J; Min, Z; Rapsinski, GJ | 1 |
| Brockhurst, MA; Davies, EV; James, CE; Winstanley, C | 1 |
| Gentry, CA; Williams, RJ | 1 |
| Belot, A; Ben Said, B; Gillet, Y; Girard, S; Hartmann-Merlin, C; Hees, L; Penel-Page, M; Phan, A | 1 |
| Lodise, TP; McNutt, LA; Patel, N | 1 |
| Castelletti, S; Chiodi, L; Cirioni, O; Gabrielli, E; Ghiselli, R; Giacometti, A; Mocchegiani, F; Orlando, F; Riva, A; Saba, V; Scalise, G; Silvestri, C | 1 |
| Alquezar, A; Castro, P; Codina, C; Delgado, E; Marco, F; Martí, S; Martínez, JA; Mensa, J; Nicolás, JM; Soriano, A; Torres, A; Trilla, A; Vila, J | 1 |
| Esposito, S; Felaco, FM; Fiore, M; Ianniello, F; Leone, S; Noviello, S; Romagnoli, F; Sarli, E | 1 |
| Cho, YB; Choi, CH; Jang, CH; Park, H; Park, IY | 1 |
| Akinci, E; Balaban, N; Baran, G; Bodur, H; Cevik, MA; Erbay, A; Onguru, P | 1 |
| Adukauskiene, D; Dambrauskiene, A; Jeroch, J; Vitkauskiene, A | 1 |
| Bou, G; Torres, E; Villanueva, R | 1 |
| Fujimura, S; Nakano, Y; Takane, H; Watanabe, A | 1 |
| Jones, RN; Rhomberg, PR; Sader, HS; Stilwell, MG | 1 |
| Doherty, JA; Khan, J; Kollef, MH; Micek, ST; Pervez, M; Reichley, RM; Welch, EC | 1 |
| Enkhbaatar, P; Maybauer, DM; Maybauer, MO; Nakano, Y; Traber, DL | 1 |
| Chew, FL; Samsudin, A; Shin, HC; Soong, TK; Visvaraja, S | 1 |
| Bai, H; He, G; Hou, Z; Jia, M; Luo, X; Ma, X; Meng, J; Wang, H; Wang, R; Yu, J | 1 |
| Bivas, A; Fraser, A; Leibovici, L; Paul, M; Yahav, D | 1 |
| Berthelot, G; Chibani, A; Etienne, M; Martin, P; Robaday, S; Suel, P | 1 |
| Ambatipudi, S; Mathai, A; Pathengay, A; Shah, GY | 1 |
| Cho, E; Davidson, AG; Lillquist, YP | 1 |
| Carillo, C; Cassani, C; Cipolloni, AP; Gagliotti, C; Gargiulo, R; Incerti, SS; Moro, ML; Pedna, F; Rossi, MR; Rossolini, GM; Sabia, C; Sarti, M; Testa, G; Venturelli, C | 1 |
| Chung, DR; Ha, YE; Joo, EJ; Kang, CI; Kang, SJ; Lee, NY; Park, SY; Peck, KR; Song, JH | 1 |
| Bosso, JA; Church, EC; Mauldin, PD | 1 |
| Mikamo, H; Miura, Y; Ohki, E; Terada, M; Umemura, T; Yamagishi, Y | 1 |
| Donnell, RW; Hickey, WS; Kaufman, SE | 1 |
| Anjum, R; Fahim, Q; Gill, MM; Hassan, A; Kaleem, F; Khalid, A; Usman, J | 1 |
| Ciombor, KK; Gehrie, E; Harris, N; Neff, AT; Seegmiller, AC; Young, PP | 1 |
| Bulik, CC; Keel, RA; Nicolau, DP; Sutherland, CA; Tessier, PR | 1 |
| Botha, JF; Fey, P; Florescu, DF; Grant, W; Kalil, AC | 1 |
| Alkhani, AM; Alshaya, WA | 1 |
| Chow, I; Ensom, MH; Mabasa, VH; Mah, GT | 1 |
| Anderson, DJ; Bennett, KM; Dotson, TL; Sarraf-Yazdi, S; Sharpe, M; Vaslef, SN | 1 |
| Carroll, KC; Cosgrove, SE; Hsu, AJ; Milstone, AM; Tamma, PD; Turnbull, AE | 1 |
| Chen, YH; Chen, YS; Chuang, YC; Ho, CM; Hsueh, PR; Huang, CC; Ko, WC; Lee, YL; Liu, CE; Liu, YC; Liu, YM; Lu, PL; Ni, Y; Tang, HJ; Toh, HS; Wang, JH; Xu, Y; Yu, KW | 1 |
| Faoagali, J; Gallagher, JE; George, N; Gidding, HF; Ginn, AN; Iredell, JR; Lipman, J; O'Driscoll, JS; O'Toole, BI; Partridge, SR; Perri, RA; Wiklendt, AM | 1 |
| Ampofo, K; Sherwin, CM; Spigarelli, MG; Stockmann, C; Waters, CD; Young, DC; Zobell, JT | 1 |
| Kaygusuz, A | 1 |
| Gilsdorf, JR | 1 |
| Kuti, JL; Nicolau, D; Nightingale, CH; Quintiliani, R | 1 |
| Andonian, S; Aprikian, AG; Rabah, DM | 1 |
| Beilman, GJ; Feltis, BA; Lee, DA | 1 |
| Ghuloom, A; Mysore, V | 1 |
| Pitt, TL; Sparrow, M; Stefanidou, M; Warner, M | 1 |
| Brunner, M; Erovic, BM; Georgopoulos, A; Joukhadar, C; Marsik, C; Müller, M; Sauermann, R; Zeitlinger, M | 1 |
| Ceran, N; Erdem, I; Kucukercan, M | 1 |
| Higaki, S; Kitagawa, T; Makino, T; Morohashi, M; Takashima, H; Yamagishi, T | 1 |
| Abe, M; Araki, M; Horimi, T; Nasu, Y; Ono, N; Takahashi, I | 1 |
| Baysallar, M; Doğanci, L; Kiliç, A; Küçükkaraaslan, A; Senses, Z | 1 |
| Evangelista, AT; Jones, ME; Karlowsky, JA; Sahm, DF; Thornsberry, C; Yee, YC | 1 |
| Akgün, H; Caner, F; Erkiliç, K; Eşel, D; Evereklioglu, C; Ozkiriş, A | 1 |
| Akgün, H; Erkiliç, K; Esel, D; Evereklioglu, C; Göktas, S; Ozkiris, A | 1 |
| Hameed, S; Johnson, M; Lipman, M; Tariq, S; Tyrer, M | 1 |
| Erovic, BM; Georgopoulos, A; Joukhadar, C; Müller, M; Sauermann, R; Zeitlinger, MA | 1 |
| Kotapati, S; Kuti, JL; Nicolau, DP | 1 |
| Alireza, S; Gholamali, G; Javad, A; Kazem, G; Qulamreza, K; Vahid, P | 1 |
| Chan, E; Duan, W; Srikumar, S; Zhou, S | 1 |
| Leitner, E; Lode, H; Schmitt, DV; Welte, T | 1 |
| Chastre, J; Combes, A; Fagon, JY; Luyt, CE; Trouillet, JL; Wolff, M | 1 |
| Drusano, GL; Lodise, TP; Lomaestro, B | 1 |
| Tucker, H; Wu, D | 1 |
| Glück, T; Herzig, H; Kees, F; Langgartner, J; Lehn, N | 1 |
| Akova, M; Altun, B; Gürkan Aydin, N; Hasçelik, G; Metan, G; Zarakolu, P | 1 |
| Aydin, K; Caylan, R; Koksal, I; Ozgumus, OB; Sandalli, C; Tosun, I | 1 |
| Kim, A; Kuti, JL; Nicolau, DP; Sutherland, CA | 1 |
| Cirioni, O; Ghiselli, R; Giacometti, A; Giovanni, M; Kamysz, E; Kamysz, W; Minardi, D; Orlando, F; Parri, G; Saba, V; Scalise, G; Silvestri, C | 1 |
| Ikonomidis, A; Kantzanou, M; Maniatis, AN; Neou, E; Pournaras, S; Tsakris, A | 1 |
| Caeiro, JP; Gamez, EA; Garey, KW; Gentry, LO; Gerard, LN; Larocco, MT; Tam, VH; Weston, JS | 1 |
| Batten, JC; Hodson, ME; Kennedy, HG; Stead, RJ | 2 |
| Strandvik, B | 1 |
| Dickinson, GM; Droller, DG; Greenman, RL; Hoffman, TA | 1 |
| Thieme, H; Tunn, UW | 1 |
| Brückner, O; Hahn, H; Trautmann, M | 1 |
| Ott, PM; Vogt, M | 1 |
| Nishino, T; Saito, M; Shibata, K; Tanino, T | 1 |
| Eron, LJ; Goldenberg, RI; Park, CH; Poretz, DM | 1 |
| Neu, HC; Prince, AS | 2 |
| Agostini, M; Barlocco, G; Bonomi, U; Borgo, G; Bozzino, L; Cabrini, G; Cappelletti, LM; Castellani, L; Conforti, M; Mastella, G | 1 |
| Babin, S; Blessing-Moore, J; Hsu, YP; Lewiston, NJ; Moss, RB | 1 |
| Fleming, PC; Gold, R; Isles, A; Jin, E; Levison, H | 1 |
| Haag, R | 1 |
| Gorbach, SL; Simon, GL; Snydman, DR; Tally, FP | 1 |
| Black, S; Grossman, M; Sherman, P | 1 |
| George, CR; Guinness, MD | 1 |
| Høiby, N; Møller, NE | 1 |
| Morris, WT; Say, PJ | 1 |
| Endo, K; Imamura, K; Kumasaka, Y; Masaki, N; Matsuhashi, A; Nakahata, H; Narita, S; Sasaki, K; Takebe, K; Tamura, T | 1 |
| Eriksen, KR; Feddersen, C; Flensborg, EW; Høiby, N; Møller, NE; Norn, S; Rosendal, K; Schiøtz, PO; Skov, PS | 1 |
| Barnes, RC; Champlin, RE; Gale, RP; Ho, WG; Winston, DJ; Young, LS | 1 |
| Pennington, JE; Schiff, JB | 1 |
| Aronoff, SC; Klinger, JD | 1 |
| Hoogkamp-Korstanje, JA; van der Laag, J | 1 |
| Ciofu, O; Giwercman, B; Høiby, N; Pedersen, SS | 1 |
| Campo, RE; Melnick, SJ; Ratzan, KR | 1 |
| Deng, GH | 1 |
| Goto, S; Hasegawa, M; Kobayashi, I; Miyazaki, S; Nishida, M | 1 |
| Klepser, ME; Nicolau, DP; Nightingale, CH; Patel, KB; Quintiliani, R | 1 |
| Hendricks, MK; Senekal, M | 1 |
| Heggers, JP; Herndon, DN; Villarreal, C; Walton, MA | 1 |
| Kokontis, L; Malanga, CJ; Mauzy, S | 1 |
| Ambrosetti, P; Aymon, D; Bille, J; Chiolero, R; Cometta, A; Glauser, MP; Harbarth, S; Huber, O; Jaccard, C; Lew, D; Praz, G; Ricou, B; Romand, J; Schneider, R; Troillet, N; Zanetti, G | 1 |
| Ikeda, N; Matsuyama, N; Watanabe, K | 1 |
| Kepple, SR | 1 |
| Elhelali, N; Jacolot, A; Laurent, F; Léotard, S; Mimoz, O; Nordmann, P; Petitjean, O; Samii, K | 1 |
| Kamiya, A; Mizuno, H; Oie, S; Sawa, A | 1 |
| Kakizaki, Y; Sugimoto, K; Tanaka, H; Tateyama, T; Waga, S; Yokoyama, M | 1 |
| Burgess, DS; Hastings, RW | 1 |
| Coia, JE; Gillespie, TA; Hanson, MF; Johnson, PR; Notman, AW | 1 |
| Harris, AD; Johnson, JA; Kaye, KS; Morris, G; Perencevich, E; Roghmann, MC | 1 |
| Capitano, B; Kim, MK; Mattoes, HM; Nicolau, DP; Nightingale, CH; Quintiliani, R; Xuan, D | 1 |
| Dutova, EN; Nasonov, VN; Nekhorosheva, AG; Savitskaia, KI; Skala, LZ | 1 |
| Zhang, YP | 1 |
| Tzamaloukas, AH | 1 |
| Bercault, N; Demasure, M; Gueveler, C; Martin, P; Poisson, D | 1 |
| Bromley, HR; Brundage, DM; Brundage, RC; Uber, WE; White, RL | 1 |
| Kikuchi, K | 1 |
| Araki, H; Kurokawa, Y; Minami, S; Nakahama, C; Saikawa, I; Soejima, R; Ueda, S; Watanabe, Y; Yamada, M; Yasuda, T | 1 |
| De Boeck, K; Eggermont, E; Smet, M | 1 |
| Mylotte, JM; Pasko, MT; Tisdale, JE | 1 |
| Li, JT | 1 |
| Chin, NX; Jules, K; Neu, HC | 1 |
| Bentzon, MW; Høiby, N; Jensen, T; Koch, C; Pedersen, SS; Pressler, T; Rosdahl, VT | 1 |
| Letendre, ED; Mantha, R; Turgeon, PL | 1 |
| Aoki, A; Gato, S; Saigusa, M; Shiritani, Y; Tsuji, A; Yamaji, S; Yokoiyama, S | 1 |
| Nightingale, CH; Quintiliani, R; Zhi, JG | 2 |
| Cambisano, W; Costantini, D; Crossignani, RM; Danza, ML; Giunta, A; Padoan, R; Trezzi, G | 1 |
| Black, P; Blumer, J; Craft, JC; Halsey, NA; McCarty, JM; Tilden, SJ; Waring, W | 1 |
| Jimenez-Lucho, VE; Medeiros, AA; Pohlod, D; Saravolatz, LD | 1 |
| Fu, KP; Gregory, FJ; Hetzel, N; Hung, PP | 1 |
| Del Piero, E; Leopold, I; Pennett, M | 1 |
| Grassi, C | 1 |
| Calia, FM; Johnson, DE; Thompson, B | 1 |
| Fox, CL; Modak, S | 1 |
| Benuck, I; Traisman, HS | 1 |
| Kirkwood, CF; Lasezkay, GM | 1 |
| Angelopulos, CM; Dick, JD; Goldberger, SP; Green, L | 1 |
| Boldur, I; Karpuch, J; Milo, R; Sarfati, S; Schiffer, J | 1 |
10 review(s) available for piperacillin and Pseudomonas Infections
| Article | Year |
|---|---|
Liver abscess caused by multidrug-resistant Pseudomonas aeruginosa treated with colistin; a case report and review of the literature.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; Cephalosporins; Cholangitis; Colistin; Drug Resistance, Multiple, Bacterial; Humans; Kidney; Liver Abscess, Pyogenic; Male; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections | 2013 |
Multidrug-resistant Pseudomonas aeruginosa endophthalmitis in a silicone oil-filled eye treated with piperacillin/tazobactam: report of a case and review of literature.
Topics: Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Endophthalmitis; Humans; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Postoperative Complications; Pseudomonas aeruginosa; Pseudomonas Infections; Retinal Detachment; Retinal Perforations; Silicone Oils; Visual Acuity; Vitrectomy; Young Adult | 2015 |
Anti-pseudomonal beta-lactams for the initial, empirical, treatment of febrile neutropenia: comparison of beta-lactams.
Topics: Anti-Bacterial Agents; beta-Lactams; Cefepime; Ceftazidime; Cephalosporins; Fever; Humans; Imipenem; Meropenem; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Randomized Controlled Trials as Topic; Thienamycins | 2010 |
Rationale and evidence for extended infusion of piperacillin-tazobactam.
Topics: Animals; Anti-Bacterial Agents; Humans; Infusions, Intravenous; Length of Stay; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Time Factors | 2011 |
Evaluating outcomes associated with alternative dosing strategies for piperacillin/tazobactam: a qualitative systematic review.
Topics: Anti-Bacterial Agents; Drug Administration Schedule; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Treatment Outcome | 2012 |
Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: II. cephalosporins and penicillins.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; Cefepime; Ceftazidime; Cephalosporins; Clavulanic Acids; Cystic Fibrosis; Disease Progression; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Penicillins; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Ticarcillin | 2013 |
Mycotic aneurysm of the descending thoracic aorta caused by Pseudomonas aeruginosa in a solid organ transplant recipient: case report and review.
Topics: Adult; Aneurysm, Infected; Aortic Aneurysm, Thoracic; Aztreonam; Blood Vessel Prosthesis Implantation; Debridement; Drug Therapy, Combination; Humans; Infusions, Parenteral; Male; Organ Transplantation; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas Infections; Secondary Prevention; Treatment Outcome; Vancomycin | 2002 |
[Pseudomonas aeruginosa pneumonia].
Topics: Cefoperazone; Cephalosporins; Diagnosis, Differential; Humans; Immunocompromised Host; Penicillins; Piperacillin; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections | 1999 |
[Characteristics of the anti-Pseudomonas aeruginosa activity of ureidopenicillins and recent advances in their research].
Topics: Azlocillin; Penicillin Resistance; Penicillins; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections | 1989 |
Respiratory infections: clinical evaluation.
Topics: Amikacin; Carbenicillin; Cefotaxime; Cystic Fibrosis; Drug Therapy, Combination; Enterobacteriaceae; Haemophilus influenzae; Humans; Piperacillin; Pseudomonas Infections; Respiratory Tract Infections; Streptococcus; Streptococcus pneumoniae; Tobramycin | 1985 |
17 trial(s) available for piperacillin and Pseudomonas Infections
| Article | Year |
|---|---|
Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers.
Topics: Adult; Anti-Bacterial Agents; Case-Control Studies; Computer Simulation; Cystic Fibrosis; Female; Half-Life; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Microbial Sensitivity Tests; Monte Carlo Method; Piperacillin; Population; Pseudomonas aeruginosa; Pseudomonas Infections | 2007 |
Pharmacokinetics and pharmacodynamics of extended-infusion piperacillin/tazobactam in adult patients with cystic fibrosis-related acute pulmonary exacerbations.
Topics: Adult; Anti-Bacterial Agents; Cystic Fibrosis; Female; Humans; Infusions, Intravenous; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Serum; Time Factors; Treatment Outcome; Young Adult | 2014 |
Population pharmacokinetics of the piperacillin component of piperacillin/tazobactam in pediatric oncology patients with fever and neutropenia.
Topics: Anti-Bacterial Agents; Child; Child, Preschool; Female; Fever; Humans; Male; Models, Biological; Neoplasms; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections | 2015 |
Continuous versus intermittent piperacillin/tazobactam infusion in infection due to or suspected pseudomonas aeruginosa.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Load; Cross Infection; Double-Blind Method; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Remission Induction; Spain; Time Factors; Treatment Outcome; Young Adult | 2016 |
Piperacillin/tazobactam vs imipenem/cilastatin in the treatment of nosocomial pneumonia--a double blind prospective multicentre study.
Topics: Adult; Cilastatin; Cross Infection; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Imipenem; Male; Penicillanic Acid; Piperacillin; Pneumonia; Prospective Studies; Pseudomonas Infections; Tazobactam; Treatment Outcome | 2006 |
Impact of piperacillin resistance on the outcome of Pseudomonas ventilator-associated pneumonia.
Topics: Aged; Anti-Bacterial Agents; Bronchoscopy; Drug Resistance, Bacterial; Female; Humans; Intensive Care Units; Logistic Models; Male; Middle Aged; Outcome Assessment, Health Care; Piperacillin; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections; Severity of Illness Index | 2006 |
Comparison of the pharmacokinetics of piperacillin and sulbactam during intermittent and continuous intravenous infusion.
Topics: Aged; Cross-Over Studies; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Piperacillin; Pseudomonas Infections; Sulbactam | 2007 |
Alternative antibiotics for the treatment of Pseudomonas infections in cystic fibrosis.
Topics: Adolescent; Alcohol Deterrents; Anti-Bacterial Agents; Azlocillin; Cefoperazone; Cefotaxime; Cefsulodin; Ceftazidime; Cephalosporins; Child; Clinical Trials as Topic; Cystic Fibrosis; Double-Blind Method; Eosinophilia; Humans; Moxalactam; Penicillins; Piperacillin; Pseudomonas Infections; Random Allocation; Respiratory Tract Infections | 1983 |
Clinical trial of piperacillin with acquisition of resistance by Pseudomonas and clinical relapse.
Topics: Adolescent; Adult; Aged; Carbenicillin; Clinical Trials as Topic; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Penicillin Resistance; Penicillins; Piperacillin; Pseudomonas; Pseudomonas Infections; Recurrence; Sepsis; Urinary Tract Infections | 1980 |
Piperacillin in surgical infections: a clinical trial.
Topics: Clinical Trials as Topic; Humans; Penicillins; Piperacillin; Pseudomonas Infections; Staphylococcal Infections; Surgical Wound Infection | 1981 |
Piperacillin and tobramycin in the treatment of Pseudomonas lung infections in cystic fibrosis.
Topics: Adolescent; Child; Cystic Fibrosis; Drug Therapy, Combination; Humans; Lung Diseases; Piperacillin; Pseudomonas Infections; Tobramycin | 1983 |
Comparison of the bactericidal activities of ofloxacin and ciprofloxacin alone and in combination with ceftazidime and piperacillin against clinical strains of Pseudomonas aeruginosa.
Topics: Adult; Anti-Infective Agents; Ceftazidime; Cephalosporins; Ciprofloxacin; Cross-Over Studies; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Half-Life; Humans; Male; Microbial Sensitivity Tests; Ofloxacin; Penicillins; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Serum Bactericidal Test | 1995 |
Prospective randomized comparison of imipenem-cilastatin and piperacillin-tazobactam in nosocomial pneumonia or peritonitis.
Topics: Acute Disease; Adult; Aged; Cilastatin; Cilastatin, Imipenem Drug Combination; Cross Infection; Drug Combinations; Drug Therapy, Combination; Female; Humans; Imipenem; Male; Middle Aged; Penicillanic Acid; Peritonitis; Piperacillin; Pneumonia; Prospective Studies; Pseudomonas Infections; Tazobactam | 1998 |
Comparative pharmacokinetic and pharmacodynamic profile of piperacillin/tazobactam 3.375G Q4H and 4.5G Q6H.
Topics: Adult; Area Under Curve; Chromatography, High Pressure Liquid; Cross-Over Studies; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections | 2002 |
Treatment of Pseudomonas lung infection in cystic fibrosis with piperacillin plus tobramycin versus ceftazidime monotherapy: preliminary communication.
Topics: Ceftazidime; Chronic Disease; Cystic Fibrosis; Drug Combinations; Forced Expiratory Volume; Humans; Leukocyte Count; Lung Diseases; Neutrophils; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Random Allocation; Tobramycin; Vital Capacity | 1989 |
Ceftazidime monotherapy vs. combined therapy in Pseudomonas pulmonary infections in cystic fibrosis.
Topics: Adolescent; Adult; Analysis of Variance; Ceftazidime; Child; Child, Preschool; Cystic Fibrosis; Drug Therapy, Combination; Female; Humans; Male; Piperacillin; Pneumonia; Prospective Studies; Pseudomonas; Pseudomonas Infections; Random Allocation; Sisomicin; Sputum | 1987 |
Comparison of piperacillin alone versus piperacillin plus tobramycin for treatment of respiratory infections in children with cystic fibrosis.
Topics: Child; Child, Preschool; Cystic Fibrosis; Drug Therapy, Combination; Half-Life; Humans; Infant; Piperacillin; Pseudomonas Infections; Random Allocation; Respiratory Tract Infections; Sputum; Tobramycin | 1988 |
195 other study(ies) available for piperacillin and Pseudomonas Infections
| Article | Year |
|---|---|
Development and persistence of antimicrobial resistance in Pseudomonas aeruginosa: a longitudinal observation in mechanically ventilated patients.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Drug Resistance, Bacterial; Humans; Longitudinal Studies; Pneumonia, Ventilator-Associated; Polymerase Chain Reaction; Pseudomonas aeruginosa; Pseudomonas Infections | 2007 |
Effects of carbapenem exposure on the risk for digestive tract carriage of intensive care unit-endemic carbapenem-resistant Pseudomonas aeruginosa strains in critically ill patients.
Topics: Adult; Aged; Anti-Bacterial Agents; beta-Lactam Resistance; Carbapenems; Carrier State; Critical Illness; Endemic Diseases; Female; Gastrointestinal Tract; Humans; Imipenem; Incidence; Intensive Care Units; Male; Middle Aged; Pharynx; Pseudomonas aeruginosa; Pseudomonas Infections; Rectum; Risk Factors | 2007 |
Genetic structures at the origin of acquisition of the beta-lactamase bla KPC gene.
Topics: Base Sequence; beta-Lactamases; beta-Lactams; Cloning, Molecular; Colombia; DNA Transposable Elements; Greece; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Molecular Sequence Data; Pseudomonas aeruginosa; Pseudomonas Infections; Sequence Analysis, DNA; United States | 2008 |
Synergy between polyethylenimine and different families of antibiotics against a resistant clinical isolate of Pseudomonas aeruginosa.
Topics: Aminoglycosides; Anti-Bacterial Agents; Carbenicillin; Ceftazidime; Ciprofloxacin; Drug Resistance, Bacterial; Drug Synergism; Humans; Microbial Sensitivity Tests; Novobiocin; Ofloxacin; Piperacillin; Polyethyleneimine; Pseudomonas aeruginosa; Pseudomonas Infections; Rifampin; Ticarcillin; Tobramycin | 2008 |
Metallo-beta-lactamase gene bla(IMP-15) in a class 1 integron, In95, from Pseudomonas aeruginosa clinical isolates from a hospital in Mexico.
Topics: Bacterial Proteins; beta-Lactamases; Cross Infection; Electrophoresis, Gel, Pulsed-Field; Humans; Integrons; Mexico; Models, Genetic; Molecular Sequence Data; Pseudomonas aeruginosa; Pseudomonas Infections | 2008 |
Characterization of the new metallo-beta-lactamase VIM-13 and its integron-borne gene from a Pseudomonas aeruginosa clinical isolate in Spain.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; Base Sequence; beta-Lactam Resistance; beta-Lactamases; Cloning, Molecular; DNA Primers; DNA, Bacterial; Genes, Bacterial; Genetic Variation; Humans; Imipenem; Integrons; Kinetics; Meropenem; Molecular Sequence Data; Phylogeny; Pseudomonas aeruginosa; Pseudomonas Infections; Recombinant Proteins; Sequence Homology, Amino Acid; Spain; Thienamycins | 2008 |
Fluoroquinolone enhances the mutation frequency for meropenem-selected carbapenem resistance in Pseudomonas aeruginosa, but use of the high-potency drug doripenem inhibits mutant formation.
Topics: Base Sequence; beta-Lactam Resistance; Carbapenems; DNA Primers; DNA, Bacterial; Doripenem; Fluoroquinolones; Genes, Bacterial; Humans; In Vitro Techniques; Meropenem; Mutation; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2008 |
Role of ampD homologs in overproduction of AmpC in clinical isolates of Pseudomonas aeruginosa.
Topics: Amino Acid Sequence; Bacterial Proteins; Base Sequence; beta-Lactam Resistance; beta-Lactamases; DNA Primers; DNA, Bacterial; Gene Expression Regulation, Bacterial; Gene Expression Regulation, Enzymologic; Genes, Bacterial; Genetic Complementation Test; Humans; Molecular Sequence Data; N-Acetylmuramoyl-L-alanine Amidase; Pseudomonas aeruginosa; Pseudomonas Infections; RNA, Bacterial; Sequence Homology, Amino Acid | 2008 |
First organisms with acquired metallo-beta-lactamases (IMP-13, IMP-22, and VIM-2) reported in Austria.
Topics: Austria; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; beta-Lactams; Humans; Microbial Sensitivity Tests; Molecular Sequence Data; Pseudomonas aeruginosa; Pseudomonas Infections; Sequence Analysis, DNA | 2009 |
Diversity of beta-lactamases produced by ceftazidime-resistant Pseudomonas aeruginosa isolates causing bloodstream infections in Brazil.
Topics: Aminoglycosides; Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Brazil; Carbapenems; Ceftazidime; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Humans; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolones | 2009 |
Detection of the novel extended-spectrum beta-lactamase OXA-161 from a plasmid-located integron in Pseudomonas aeruginosa clinical isolates from Spain.
Topics: Amikacin; Aminoglycosides; Anti-Bacterial Agents; beta-Lactamases; Cefepime; Cephalosporins; Clavulanic Acid; Gentamicins; Humans; Imipenem; Integrons; Meropenem; Molecular Sequence Data; Penicillanic Acid; Piperacillin; Plasmids; Pseudomonas aeruginosa; Pseudomonas Infections; Spain; Tazobactam; Thienamycins | 2009 |
In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa.
Topics: Animals; Anti-Bacterial Agents; Carbapenems; Doripenem; Drug Administration Schedule; Female; Humans; Mice; Pseudomonas aeruginosa; Pseudomonas Infections | 2009 |
Molecular and biochemical characterization of the natural chromosome-encoded class A beta-lactamase from Pseudomonas luteola.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; beta-Lactamases; Catheters, Indwelling; Chromosomes, Bacterial; Cloning, Molecular; Electrophoresis, Gel, Pulsed-Field; Genes, Bacterial; Genetic Variation; Isoelectric Focusing; Kinetics; Microbial Sensitivity Tests; Molecular Sequence Data; Phylogeny; Plasmids; Pseudomonas; Pseudomonas Infections; Recombinant Proteins; Reverse Transcriptase Polymerase Chain Reaction; Substrate Specificity | 2010 |
BEL-2, an extended-spectrum beta-lactamase with increased activity toward expanded-spectrum cephalosporins in Pseudomonas aeruginosa.
Topics: Belgium; beta-Lactamases; Cephalosporinase; Cephalosporins; Cross Infection; Escherichia coli; Genes, Bacterial; Humans; Kinetics; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2010 |
Activity of a new antipseudomonal cephalosporin, CXA-101 (FR264205), against carbapenem-resistant and multidrug-resistant Pseudomonas aeruginosa clinical strains.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Cephalosporins; Drug Resistance, Multiple, Bacterial; Humans; Isoelectric Focusing; Microbial Sensitivity Tests; Polymerase Chain Reaction; Pseudomonas aeruginosa; Pseudomonas Infections | 2010 |
GES-13, a beta-lactamase variant possessing Lys-104 and Asn-170 in Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactamases; beta-Lactams; Cephalosporins; Genetic Variation; Humans; Integrons; Microbial Sensitivity Tests; Molecular Sequence Data; Pseudomonas aeruginosa; Pseudomonas Infections; Sequence Analysis, DNA | 2010 |
Activity of a new cephalosporin, CXA-101 (FR264205), against beta-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Cephalosporins; Cross Infection; Humans; Intensive Care Units; Microbial Sensitivity Tests; Mutation; Pseudomonas aeruginosa; Pseudomonas Infections | 2010 |
Characterization of DIM-1, an integron-encoded metallo-beta-lactamase from a Pseudomonas stutzeri clinical isolate in the Netherlands.
Topics: Amino Acid Sequence; Bacterial Proteins; Base Sequence; beta-Lactamases; Cloning, Molecular; DNA, Bacterial; Drug Resistance, Bacterial; Genes, Bacterial; Humans; Integrons; Middle Aged; Molecular Sequence Data; Netherlands; Pseudomonas Infections; Pseudomonas stutzeri; Sequence Homology, Amino Acid; Substrate Specificity | 2010 |
First survey of metallo-beta-lactamases in clinical isolates of Pseudomonas aeruginosa in a German university hospital.
Topics: Anti-Bacterial Agents; beta-Lactamases; Ceftazidime; Drug Resistance, Bacterial; Germany; Hospitals, University; Humans; Imipenem; Microbial Sensitivity Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2010 |
Nationwide investigation of extended-spectrum beta-lactamases, metallo-beta-lactamases, and extended-spectrum oxacillinases produced by ceftazidime-resistant Pseudomonas aeruginosa strains in France.
Topics: Anti-Bacterial Agents; beta-Lactamases; Ceftazidime; Cephalosporin Resistance; France; Humans; Microbial Sensitivity Tests; Prevalence; Pseudomonas aeruginosa; Pseudomonas Infections | 2010 |
Design, Synthesis, and Properties of a Potent Inhibitor of Pseudomonas aeruginosa Deacetylase LpxC.
Topics: Amidohydrolases; Animals; Anti-Bacterial Agents; Chemistry Techniques, Synthetic; Crystallography, X-Ray; Drug Design; Drug Evaluation, Preclinical; Drug Resistance, Multiple, Bacterial; Enzyme Inhibitors; Female; Hep G2 Cells; Humans; K562 Cells; Mice, Inbred BALB C; Microbial Sensitivity Tests; Molecular Docking Simulation; Pseudomonas aeruginosa; Pseudomonas Infections; Structure-Activity Relationship | 2017 |
Antimicrobial resistance, virulence factors, and genotypes of Pseudomonas aeruginosa clinical isolates from Gorgan, northern Iran.
Topics: Amikacin; Anti-Bacterial Agents; Ceftazidime; Ciprofloxacin; Colistin; Deoxyribonucleases; Drug Resistance, Bacterial; Genotype; Gentamicins; Humans; Imipenem; Iran; Levofloxacin; Meropenem; Microbial Sensitivity Tests; Pancreatic Elastase; Phospholipases; Piperacillin; Piperacillin, Tazobactam Drug Combination; Polymyxin B; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Virulence Factors | 2022 |
Molecular investigation of prevalence, phenotypic and genotypic diversity, antibiotic resistance, frequency of virulence genes and genome sequencing in Pseudomonas aeruginosa strains isolated from lobster.
Topics: Animals; Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Humans; Microbial Sensitivity Tests; Nephropidae; Piperacillin; Prevalence; Pseudomonas aeruginosa; Pseudomonas Infections; Virulence; Virulence Factors | 2022 |
Deconstructing the 2023 Clinical and Laboratory Standards Institute Revised Piperacillin-Tazobactam Breakpoints Against Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections | 2023 |
Ciprofloxacin resistance and tolerance of Pseudomonas aeruginosa ocular isolates.
Topics: Agar; Anti-Bacterial Agents; Ceftazidime; Ciprofloxacin; Gentamicins; Humans; Imipenem; Keratitis; Levofloxacin; Microbial Sensitivity Tests; Piperacillin; Polymyxin B; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2023 |
Evaluated gene expressions of Metallo beta lactamase genes GIM and , VIM, SPM in Pseudomonas aeruginosa clinical isolates.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbapenems; Child; Ciprofloxacin; Gene Expression; Humans; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Real-Time Polymerase Chain Reaction; RNA, Ribosomal, 16S | 2023 |
Population Pharmacokinetics and Safety of Piperacillin-Tazobactam Extended Infusions in Infants and Children.
Topics: Anti-Bacterial Agents; Child; Child, Preschool; Cross Infection; Female; Humans; Infant; Male; Microbial Sensitivity Tests; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2019 |
Potency of Vaborbactam Is Less Affected than That of Avibactam in Strains Producing KPC-2 Mutations That Confer Resistance to Ceftazidime-Avibactam.
Topics: Amino Acid Substitution; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactamases; Boronic Acids; Cefepime; Ceftazidime; Drug Combinations; Drug Resistance, Multiple, Bacterial; Humans; Klebsiella Infections; Klebsiella pneumoniae; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections | 2020 |
Time above the MIC of Piperacillin-Tazobactam as a Predictor of Outcome in Pseudomonas aeruginosa Bacteremia.
Topics: Adult; Anti-Bacterial Agents; Bacteremia; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies | 2020 |
Efficacy of sub-MIC level of meropenem and ciprofloxacin against extensive drug-resistant (XDR) Pseudomonas aeruginosa isolates of diabetic foot ulcer patients.
Topics: Anti-Bacterial Agents; Cephalosporins; Ciprofloxacin; Diabetic Foot; Drug Resistance; Humans; Meropenem; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2021 |
Outpatient therapy with piperacillin/tazobactam using elastomeric pumps in patients with Pseudomonas aeruginosa infection.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Female; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Recurrence, Local; Outpatients; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies | 2021 |
The clinical significance of pneumonia in patients with respiratory specimens harbouring multidrug-resistant Pseudomonas aeruginosa: a 5-year retrospective study following 5667 patients in four general ICUs.
Topics: Aged; Amikacin; Anti-Bacterial Agents; Case-Control Studies; Colistin; Drug Resistance, Multiple, Bacterial; Female; Humans; Immunocompromised Host; Intensive Care Units; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Ventilators, Mechanical | 2017 |
Empiric antibiotic protocols for cancer patients with neutropenia: a single-center study of treatment efficacy and mortality in patients with bacteremia.
Topics: Adult; Anti-Bacterial Agents; Bacteremia; Blood Culture; Carbapenem-Resistant Enterobacteriaceae; Cefazolin; Clinical Protocols; Enterobacteriaceae Infections; Gentamicins; Humans; Imipenem; Microbial Sensitivity Tests; Middle Aged; Neoplasms; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Staphylococcal Infections; Staphylococcus aureus; Streptococcal Infections; Streptococcus | 2018 |
Topics: Adult; Anti-Bacterial Agents; Diagnosis, Differential; Female; Humans; Immunocompromised Host; Lung Diseases; Lupus Erythematosus, Systemic; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tomography, X-Ray Computed | 2017 |
Clinical characteristics and outcomes of Pseudomonas aeruginosa bacteremia in febrile neutropenic children and adolescents with the impact of antibiotic resistance: a retrospective study.
Topics: Adolescent; Amikacin; Aminoglycosides; Anti-Bacterial Agents; Bacteremia; Carbapenems; Cephalosporins; Child; Child, Preschool; Drug Resistance, Multiple, Bacterial; Female; Fever; Fluoroquinolones; Humans; Male; Meropenem; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Thienamycins | 2017 |
Exacerbation of bronchiectasis by Pseudomonas monteilii: a case report.
Topics: Adult; Bronchiectasis; Humans; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas; Pseudomonas Infections; Random Amplified Polymorphic DNA Technique; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2017 |
Topics: Anti-Bacterial Agents; Cefepime; Ceftazidime; Cephalosporins; Ciprofloxacin; Drug Combinations; Drug Resistance, Multiple, Bacterial; Febrile Neutropenia; Humans; Iatrogenic Disease; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia; Practice Guidelines as Topic; Pseudomonas aeruginosa; Pseudomonas Infections; Sepsis; Tazobactam; Thienamycins; Tobramycin | 2017 |
Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates.
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactam Resistance; beta-Lactamases; Cefepime; Ceftazidime; Cephalosporins; Drug Combinations; Gene Expression; Humans; Los Angeles; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thienamycins | 2017 |
Antimicrobial Activity of Ceftolozane-Tazobactam Tested Against Enterobacteriaceae and Pseudomonas aeruginosa with Various Resistance Patterns Isolated in U.S. Hospitals (2013-2016) as Part of the Surveillance Program: Program to Assess Ceftolozane-Tazoba
Topics: Amikacin; Anti-Bacterial Agents; Cephalosporins; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Hospitals; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thienamycins | 2018 |
Differences in suppression of regrowth and resistance despite similar initial bacterial killing for meropenem and piperacillin/tazobactam against Pseudomonas aeruginosa and Escherichia coli.
Topics: Anti-Bacterial Agents; beta-Lactam Resistance; beta-Lactamase Inhibitors; Escherichia coli; Escherichia coli Infections; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2018 |
Effects of pH on the Antibiotic Resistance of Bacteria Recovered from Diabetic Foot Ulcer Fluid
Topics: Anti-Bacterial Agents; Diabetic Foot; Drug Resistance, Microbial; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Staphylococcal Infections; Wound Healing | 2018 |
Nephrotoxicity of piperacillin/tazobactam combined with vancomycin: should it be a concern?
Topics: Acute Kidney Injury; Adult; Aged; Creatinine; Drug Therapy, Combination; Female; Humans; Kidney; Logistic Models; Male; Meropenem; Methicillin-Resistant Staphylococcus aureus; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Staphylococcal Infections; Thienamycins; Vancomycin | 2018 |
Antimicrobial Susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa Isolates from United States Medical Centers Stratified by Infection Type: Results from the International Network for Optimal Resistance Monitoring (INFORM) Surveillance Program,
Topics: Anti-Bacterial Agents; Azabicyclo Compounds; Ceftazidime; Colistin; Cross Infection; Drug Combinations; Drug Resistance, Multiple, Bacterial; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins; United States | 2018 |
Topics: Aged; Anti-Bacterial Agents; Azithromycin; Campylobacter Infections; Coinfection; Colitis, Ulcerative; Feces; Female; Fever; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas Infections; Sigmoidoscopy; Treatment Outcome | 2018 |
An α-Lipoic acid derivative, and anti-ROS agent, prevents the acquisition of multi-drug resistance in clinical isolates of Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Antioxidants; Bacterial Outer Membrane Proteins; Drug Resistance, Multiple, Bacterial; Histidine; Humans; Hydrogen Peroxide; Levofloxacin; Membrane Transport Proteins; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Reactive Oxygen Species; Thioctic Acid | 2019 |
Rapidly enlarging, giant hepatic cyst growing pseudomonas.
Topics: Aged; Anti-Bacterial Agents; Cardiac Output, Low; Cysts; Drainage; Dyspnea; Female; Humans; Liver Diseases; Metronidazole; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Tomography, X-Ray Computed; Ultrasonography, Interventional | 2019 |
In vitro interaction of various antibiotic combinations recommended by Chinese consensus statement against carbapenems-resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Aztreonam; Carbapenems; Cefoperazone; Ceftazidime; China; Cross Infection; Drug Resistance, Bacterial; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2019 |
Ceftazidime, Carbapenems, or Piperacillin-tazobactam as Single Definitive Therapy for Pseudomonas aeruginosa Bloodstream Infection: A Multisite Retrospective Study.
Topics: Anti-Bacterial Agents; Carbapenems; Ceftazidime; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies | 2020 |
Bacterial membrane disrupting dodecapeptide SC4 improves survival of mice challenged with Pseudomonas aeruginosa.
Topics: Animals; Anti-Bacterial Agents; Bacteremia; Cytokines; Disease Models, Animal; Inflammation Mediators; Male; Mice; Penicillanic Acid; Peptide Fragments; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Time Factors | 2013 |
Optimization of continuous infusion of piperacillin-tazobactam in children with fever and neutropenia.
Topics: Adolescent; Anti-Bacterial Agents; Child; Female; Fever of Unknown Origin; Humans; Infusions, Intravenous; Male; Neutropenia; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas Infections; Treatment Outcome | 2013 |
Effect of clarithromycin in experimental empyema by multidrug-resistant Pseudomonas aeruginosa.
Topics: Adjuvants, Immunologic; Animals; Anti-Bacterial Agents; Apoptosis; Clarithromycin; Disease Models, Animal; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Empyema, Pleural; Humans; Interleukin-6; Male; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pleural Effusion; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Tumor Necrosis Factor-alpha; U937 Cells | 2014 |
Impact of Bolus dosing versus continuous infusion of Piperacillin and Tazobactam on the development of antimicrobial resistance in Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Colony Count, Microbial; Computer Simulation; Drug Administration Schedule; Drug Resistance, Bacterial; Humans; Infusions, Intravenous; Microbial Sensitivity Tests; Models, Statistical; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections | 2013 |
Epidemiological and bacteriological profiles in children with burns.
Topics: Anti-Bacterial Agents; Burns; Child; Child, Preschool; Cohort Studies; Cross Infection; Drug Resistance, Bacterial; Enterobacter cloacae; Enterobacteriaceae Infections; Female; Gentamicins; Humans; Male; Oxacillin; Piperacillin; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Sepsis; Staphylococcal Infections; Staphylococcus aureus; Wound Infection | 2014 |
Effectiveness of antibiotic combination therapy as evaluated by the Break-point Checkerboard Plate method for multidrug-resistant Pseudomonas aeruginosa in clinical use.
Topics: Amikacin; Anti-Bacterial Agents; Aztreonam; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies | 2014 |
Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC.
Topics: Anti-Bacterial Agents; Bacterial Proteins; beta-Lactamases; Ceftazidime; Cephalosporins; Imipenem; Meropenem; Microbial Sensitivity Tests; Mutation; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thienamycins | 2014 |
Role of efflux pumps: MexAB-OprM and MexXY(-OprA), AmpC cephalosporinase and OprD porin in non-metallo-β-lactamase producing Pseudomonas aeruginosa isolated from cystic fibrosis and burn patients.
Topics: Amikacin; Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Bacterial Proteins; beta-Lactamases; Burns; Cephalosporinase; Cystic Fibrosis; Drug Resistance, Multiple, Bacterial; Escherichia coli Proteins; Gene Expression Regulation, Bacterial; Humans; Membrane Transport Proteins; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Porins; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2014 |
Rearrangement of a large novel Pseudomonas aeruginosa gene island in strains isolated from a patient developing ventilator-associated pneumonia.
Topics: Anti-Bacterial Agents; Clindamycin; DNA, Bacterial; Electrophoresis, Gel, Pulsed-Field; Gene Rearrangement; Genetic Variation; Genome, Bacterial; Genomic Islands; Humans; Longitudinal Studies; Molecular Typing; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Ventilator-Associated; Pseudomonas aeruginosa; Pseudomonas Infections; Sequence Analysis, DNA | 2014 |
[Whirlpool-dermatitis with "hot hands"].
Topics: Adolescent; Drug Therapy, Combination; Hand Dermatoses; Humans; Hydrotherapy; Infusions, Intravenous; Male; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Water Microbiology | 2014 |
In vivo efficacy of ceftolozane against Pseudomonas aeruginosa in a rabbit experimental model of pneumonia: comparison with ceftazidime, piperacillin/tazobactam and imipenem.
Topics: Animal Structures; Animals; Anti-Bacterial Agents; Bacterial Load; Ceftazidime; Cephalosporins; Colony Count, Microbial; Disease Models, Animal; Female; Humans; Imipenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Treatment Outcome | 2014 |
Mutation-driven β-lactam resistance mechanisms among contemporary ceftazidime-nonsusceptible Pseudomonas aeruginosa isolates from U.S. hospitals.
Topics: Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Bacterial Proteins; beta-Lactam Resistance; beta-Lactamases; Cefepime; Ceftazidime; Cephalosporins; Cross Infection; Gene Expression Regulation, Bacterial; Humans; Membrane Transport Proteins; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Porins; Pseudomonas aeruginosa; Pseudomonas Infections | 2014 |
Antibiotic therapy and clinical outcomes of Pseudomonas aeruginosa (PA) bacteraemia.
Topics: Aged; Anti-Bacterial Agents; Bacteremia; Ceftazidime; Drug Therapy, Combination; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Treatment Outcome | 2014 |
β-Lactam pharmacokinetics during extracorporeal membrane oxygenation therapy: A case-control study.
Topics: Adult; Anti-Bacterial Agents; beta-Lactams; Case-Control Studies; Extracorporeal Membrane Oxygenation; Female; Humans; Male; Meropenem; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas Infections; Sepsis; Serum; Thienamycins; Treatment Outcome | 2015 |
Clinical evaluation of the need for carbapenems to treat community-acquired and healthcare-associated pneumonia.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Carbapenems; Community-Acquired Infections; Cross Infection; Female; Hospital Mortality; Humans; Male; Middle Aged; Needs Assessment; Organizational Policy; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Prognosis; Pseudomonas Infections | 2015 |
Pharmacokinetics of an extended 4-hour infusion of piperacillin-tazobactam in critically ill patients undergoing continuous renal replacement therapy.
Topics: Aged; Anti-Bacterial Agents; Critical Illness; Female; Hemodiafiltration; Humans; Infusions, Intravenous; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Tertiary Care Centers | 2015 |
In Vitro Activity of Ceftazidime-Avibactam against Contemporary Pseudomonas aeruginosa Isolates from U.S. Medical Centers by Census Region, 2014.
Topics: Academic Medical Centers; Anti-Bacterial Agents; Azabicyclo Compounds; beta-Lactam Resistance; Ceftazidime; Censuses; Drug Combinations; Humans; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Public Health Surveillance; Thienamycins; United States | 2016 |
Protective effects of intravenous immunoglobulin and antimicrobial agents on acute pneumonia in leukopenic mice.
Topics: Animals; Anti-Bacterial Agents; Body Temperature; Colistin; Cytokines; Edema; Immunoglobulin G; Immunoglobulins, Intravenous; Leukopenia; Lung; Male; Mice; Mice, Inbred ICR; Penicillanic Acid; Peroxidase; Piperacillin; Pneumonia, Bacterial; Pre-Exposure Prophylaxis; Protective Agents; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2016 |
Targeted benefits of prolonged-infusion piperacillin-tazobactam in an in vitro infection model of Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Humans; In Vitro Techniques; Infusions, Intravenous; Microbial Sensitivity Tests; Monte Carlo Method; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections | 2016 |
Outcomes of an extended-infusion piperacillin-tazobactam protocol implementation in a community teaching hospital adult intensive care unit.
Topics: Adult; Aged; Aged, 80 and over; Case-Control Studies; Cohort Studies; Delayed-Action Preparations; Female; Hospitals, Community; Hospitals, Teaching; Humans; Intensive Care Units; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas Infections; Treatment Outcome | 2016 |
Effect of different renal function on antibacterial effects of piperacillin against Pseudomonas aeruginosa evaluated via the hollow-fibre infection model and mechanism-based modelling.
Topics: Anti-Bacterial Agents; Critical Illness; Humans; Kidney; Microbial Sensitivity Tests; Models, Theoretical; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections | 2016 |
Impact of computerized pre-authorization of broad spectrum antibiotics in Pseudomonas aeruginosa at a children's hospital in Japan.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Carbapenems; Cefepime; Ceftazidime; Cephalosporins; Hospitals; Humans; Japan; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tokyo | 2016 |
Pneumocephalus in Child Following Bilateral Otomastoiditis and Nasal Septum Infection.
Topics: Amikacin; Anti-Bacterial Agents; Humans; Infant; Male; Mastoiditis; Nasal Septum; Otitis Media; Penicillanic Acid; Piperacillin; Pneumocephalus; Pseudomonas Infections; Subdural Effusion; Tazobactam; Tomography, X-Ray Computed; Treatment Outcome | 2016 |
Real-Time Genome Sequencing of Resistant Bacteria Provides Precision Infection Control in an Institutional Setting.
Topics: Anti-Bacterial Agents; Cefotaxime; Ciprofloxacin; Cross Infection; Enterococcus faecium; Escherichia coli; Escherichia coli Infections; Genome, Bacterial; Gram-Positive Bacterial Infections; High-Throughput Nucleotide Sequencing; Humans; Infection Control; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Piperacillin; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Sequence Analysis, DNA; Staphylococcal Infections; Vancomycin-Resistant Enterococci | 2016 |
Pseudomonas mendocina native valve infective endocarditis: a case report.
Topics: Anti-Bacterial Agents; Bandages; Debridement; Endocarditis, Bacterial; Heart Valve Diseases; Humans; Leg Ulcer; Male; Middle Aged; Pain; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas Infections; Pseudomonas mendocina; Treatment Outcome | 2016 |
Evolutionary diversification of Pseudomonas aeruginosa in an artificial sputum model.
Topics: Bacteriophages; beta-Lactamases; Biodiversity; Biofilms; Biological Evolution; Culture Media; Cystic Fibrosis; Drug Resistance, Microbial; Penicillanic Acid; Phenotype; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Sputum; Tazobactam | 2017 |
A propensity score-matched analysis of the impact of minimum inhibitory concentration on mortality in patients with Pseudomonas aeruginosa bacteraemia treated with piperacillin/tazobactam.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; beta-Lactamase Inhibitors; Female; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Propensity Score; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Risk Factors; Survival Analysis | 2017 |
[Correctly adDRESS the cause of hemophagocytic lymphohistiocytosis].
Topics: Child, Preschool; Diagnosis, Differential; Drug Hypersensitivity Syndrome; Female; Humans; Lymphohistiocytosis, Hemophagocytic; Maxillary Diseases; Osteitis; Patch Tests; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections | 2017 |
Relationship between various definitions of prior antibiotic exposure and piperacillin-tazobactam resistance among patients with respiratory tract infections caused by Pseudomonas aeruginosa.
Topics: Aged; Anti-Bacterial Agents; Drug Resistance, Multiple, Bacterial; Female; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Retrospective Studies; Risk Factors | 2008 |
Protective effects of the combination of alpha-helical antimicrobial peptides and rifampicin in three rat models of Pseudomonas aeruginosa infection.
Topics: Animals; Anti-Bacterial Agents; Antimicrobial Cationic Peptides; Blood; Drug Synergism; Drug Therapy, Combination; Endotoxins; Injections, Intravenous; Magainins; Microbial Sensitivity Tests; Penicillanic Acid; Peritoneum; Piperacillin; Piperacillin, Tazobactam Drug Combination; Plasma; Pseudomonas aeruginosa; Pseudomonas Infections; Rats; Rats, Wistar; Rifampin; Survival Analysis; Treatment Outcome; Tumor Necrosis Factor-alpha; Xenopus Proteins | 2008 |
Influence of antipseudomonal agents on Pseudomonas aeruginosa colonization and acquisition of resistance in critically ill medical patients.
Topics: Adult; Cephalosporins; Critical Illness; Cross Infection; Drug Combinations; Drug Resistance, Microbial; Drug Therapy, Combination; Enzyme Inhibitors; Female; Genes, Viral; Genotype; Humans; Intensive Care Units; Male; Pharynx; Piperacillin; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolones; Rectum; Respiratory Mucosa | 2009 |
Foot infections in diabetes (DFIs) in the out-patient setting: an Italian multicentre observational survey.
Topics: Adult; Aged; Aged, 80 and over; Ambulatory Care; Anti-Bacterial Agents; Bacterial Infections; Diabetic Foot; Female; Humans; Italy; Male; Middle Aged; Outpatient Clinics, Hospital; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas Infections; Staphylococcal Infections; Young Adult | 2008 |
The use of piperacillin-tazobactam coated tympanostomy tubes against ciprofloxacin-resistant Pseudomonas biofilm formation: an in vitro study.
Topics: Anti-Bacterial Agents; Bacterial Adhesion; Bacteriological Techniques; Biofilms; Ciprofloxacin; Coated Materials, Biocompatible; Drug Resistance, Bacterial; Equipment Contamination; Equipment Design; Humans; Materials Testing; Microscopy, Electron, Scanning; Middle Ear Ventilation; Otitis Media, Suppurative; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prosthesis-Related Infections; Pseudomonas aeruginosa; Pseudomonas Infections; Silicones; Surface Properties | 2009 |
Imipenem-resistant Pseudomonas aeruginosa: risk factors for nosocomial infections.
Topics: Adult; Aged; Anti-Bacterial Agents; Case-Control Studies; Cross Infection; Drug Resistance, Multiple, Bacterial; Female; Humans; Imipenem; Length of Stay; Male; Microbial Sensitivity Tests; Middle Aged; Multivariate Analysis; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Risk Factors; Vancomycin | 2008 |
[Pseudomonas aeruginosa bacteremia: associations with a source of infection and antibiotic resistance].
Topics: Amikacin; Anti-Bacterial Agents; Bacteremia; Bacteriological Techniques; Ceftazidime; Ciprofloxacin; Drug Resistance, Bacterial; Drug Resistance, Multiple, Bacterial; Gentamicins; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections; Retrospective Studies; Thienamycins; Wound Infection | 2009 |
Comparison of different methods of determining beta-lactam susceptibility in clinical strains of Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Automation; Aztreonam; beta-Lactams; Cefepime; Ceftazidime; Cephalosporins; Genetic Predisposition to Disease; Humans; Imipenem; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections | 2009 |
In vitro synergy studies based on tazobactam/piperacillin against clinical isolates of metallo-beta-lactamase-producing Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; beta-Lactamases; Drug Synergism; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2009 |
Antipseudomonal activity of piperacillin/tazobactam: more than a decade of experience from the SENTRY Antimicrobial Surveillance Program (1997-2007).
Topics: Anti-Bacterial Agents; Global Health; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Sentinel Surveillance | 2009 |
Empiric combination antibiotic therapy is associated with improved outcome against sepsis due to Gram-negative bacteria: a retrospective analysis.
Topics: Acinetobacter Infections; Adult; Aged; Aminoglycosides; Anti-Bacterial Agents; Carbapenems; Cefepime; Cephalosporins; Cohort Studies; Drug Therapy, Combination; Escherichia coli Infections; Female; Fluoroquinolones; Gram-Negative Bacterial Infections; Hospital Mortality; Humans; Logistic Models; Male; Middle Aged; Multivariate Analysis; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Sepsis; Shock, Septic | 2010 |
A novel antibiotic based long-term model of ovine smoke inhalation injury and septic shock.
Topics: Animals; Anti-Bacterial Agents; Bacteremia; Ciprofloxacin; Disease Models, Animal; Female; Nitric Oxide; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Pulmonary Gas Exchange; Respiratory Distress Syndrome; Sheep, Domestic; Shock, Septic; Smoke Inhalation Injury; Time Factors | 2010 |
Topical piperacillin/tazobactam for recalcitrant pseudomonas aeruginosa keratitis.
Topics: Administration, Topical; Adolescent; Adult; Anti-Bacterial Agents; Corneal Ulcer; Drug Resistance; Eye Infections, Bacterial; Humans; Male; Middle Aged; Ophthalmic Solutions; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Prognosis; Pseudomonas Infections; Retrospective Studies | 2010 |
oprM as a new target for reversion of multidrug resistance in Pseudomonas aeruginosa by antisense phosphorothioate oligodeoxynucleotides.
Topics: Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Cross Infection; Dose-Response Relationship, Drug; Drug Carriers; Drug Resistance, Multiple, Bacterial; Gene Expression; Humans; Liposomes; Membrane Transport Proteins; Microbial Sensitivity Tests; Oligodeoxyribonucleotides, Antisense; Piperacillin; Polyethyleneimine; Pseudomonas aeruginosa; Pseudomonas Infections | 2010 |
[A case of Pseudomonas mendocina endocarditis].
Topics: Aged; Anti-Bacterial Agents; Aortic Valve Insufficiency; Atrial Fibrillation; Calcinosis; Disease Susceptibility; Endocarditis, Bacterial; Female; Gentamicins; Humans; Piperacillin; Pseudomonas Infections; Pseudomonas mendocina; Ultrasonography | 2011 |
Intravitreal piperacillin/tazobactam in the management of multidrug-resistant Pseudomonas aeruginosa endophthalmitis.
Topics: Anti-Bacterial Agents; Cataract Extraction; Drug Resistance, Multiple, Bacterial; Endophthalmitis; Eye Infections, Bacterial; Humans; Intravitreal Injections; Keratoplasty, Penetrating; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Visual Acuity; Vitreous Body | 2010 |
Economic effects of an eradication protocol for first appearance of Pseudomonas aeruginosa in cystic fibrosis patients: 1995 vs. 2009.
Topics: Administration, Oral; Adolescent; Anti-Bacterial Agents; Anti-Infective Agents; Burkholderia cepacia complex; Child; Child, Preschool; Ciprofloxacin; Cohort Studies; Colistin; Cystic Fibrosis; Disease-Free Survival; Drug Administration Schedule; Drug Therapy, Combination; Health Care Costs; Health Resources; Humans; Infant; Injections, Intravenous; Nebulizers and Vaporizers; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin; Treatment Outcome | 2011 |
Accuracy of automated and manual systems for susceptibility testing of Pseudomonas aeruginosa to piperacillin and piperacillin-tazobactam.
Topics: Anti-Bacterial Agents; Bacteriological Techniques; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Predictive Value of Tests; Pseudomonas aeruginosa; Pseudomonas Infections | 2011 |
Risk factors for mortality in patients with Pseudomonas aeruginosa bacteremia: clinical impact of antimicrobial resistance on outcome.
Topics: Adrenal Cortex Hormones; Aminoglycosides; Anti-Bacterial Agents; Catheters; Ceftazidime; Cross Infection; Drug Resistance, Multiple, Bacterial; Female; Fluoroquinolones; Humans; Imipenem; Male; Middle Aged; Piperacillin; Prevalence; Pseudomonas aeruginosa; Pseudomonas Infections; Republic of Korea; Retrospective Studies; Risk Factors; Survival Analysis; Treatment Outcome | 2011 |
Antibiotic resistance in Pseudomonas aeruginosa related to quinolone formulary changes: an interrupted time series analysis.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Cefepime; Cephalosporins; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Formularies, Hospital as Topic; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2011 |
Investigation of the clinical breakpoints of piperacillin-tazobactam against infections caused by Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Bacteremia; Cross Infection; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies | 2012 |
Frequency and antibiogram of multi-drug resistant Pseudomonas aeruginosa.
Topics: Anti-Bacterial Agents; Cefoperazone; Colistin; Cross-Sectional Studies; Disk Diffusion Antimicrobial Tests; Drug Resistance, Multiple, Bacterial; Enzyme Inhibitors; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Sulbactam | 2011 |
Transfusion medicine illustrated. Profound piperacillin-mediated drug-induced immune hemolysis in a patient with cystic fibrosis.
Topics: Anti-Bacterial Agents; Cystic Fibrosis; Female; Hemoglobins; Hemolysis; Humans; Piperacillin; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Young Adult | 2012 |
In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamases; Cephalosporins; Colony Count, Microbial; Disease Models, Animal; Drug Combinations; Drug Resistance, Bacterial; Escherichia coli; Escherichia coli Infections; Female; Humans; Klebsiella Infections; Klebsiella pneumoniae; Mice; Mice, Inbred ICR; Microbial Sensitivity Tests; Penicillanic Acid; Phenotype; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Thigh | 2012 |
Should multivisceral transplantation be considered in patients colonized with multidrug-resistant Pseudomonas aeruginosa?
Topics: Anti-Bacterial Agents; Antifungal Agents; Child, Preschool; Disease Management; Drug Resistance, Multiple, Bacterial; Female; Fluconazole; Humans; Intestine, Small; Kidney Transplantation; Liver Transplantation; Organ Transplantation; Pancreas Transplantation; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections | 2012 |
Pseudomonas aeruginosa osteomyelitis of the cervical spine.
Topics: Cervical Vertebrae; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Osteomyelitis; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Radiography; Smoking | 2012 |
A 9-Year retrospective review of antibiotic cycling in a surgical intensive care unit.
Topics: Anti-Bacterial Agents; Ceftazidime; Cilastatin; Cilastatin, Imipenem Drug Combination; Critical Care; Cross Infection; Drug Combinations; Drug Resistance, Bacterial; Enterobacter cloacae; Enterobacteriaceae Infections; Escherichia coli; Escherichia coli Infections; Humans; Imipenem; Infection Control; Klebsiella Infections; Klebsiella pneumoniae; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Surgical Wound Infection | 2012 |
Does the piperacillin minimum inhibitory concentration for Pseudomonas aeruginosa influence clinical outcomes of children with pseudomonal bacteremia?
Topics: Adolescent; Anti-Bacterial Agents; Bacteremia; Child; Child, Preschool; Cohort Studies; Female; Humans; Infant; Male; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Survival Analysis; Treatment Outcome | 2012 |
In vitro susceptibilities of non-Enterobacteriaceae isolates from patients with intra-abdominal infections in the Asia-Pacific region from 2003 to 2010: results from the Study for Monitoring Antimicrobial Resistance Trends (SMART).
Topics: Acinetobacter Infections; Aeromonas; Anti-Bacterial Agents; Asia; Australasia; Drug Resistance, Bacterial; Humans; Imipenem; Intraabdominal Infections; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Population Surveillance; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections | 2012 |
The ecology of antibiotic use in the ICU: homogeneous prescribing of cefepime but not tazocin selects for antibiotic resistant infection.
Topics: Adult; Aged; Anti-Bacterial Agents; Cefepime; Cephalosporins; Drug Prescriptions; Drug Resistance, Bacterial; Female; Humans; Intensive Care Units; Length of Stay; Male; Methicillin-Resistant Staphylococcus aureus; Microbial Sensitivity Tests; Middle Aged; Nasopharynx; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Staphylococcal Infections; Survival Rate | 2012 |
Infecting one animal with two different strains of the same bacteria may cause misleading results.
Topics: Abscess; Animals; Disease Models, Animal; Enzyme Inhibitors; Hindlimb; Penicillanic Acid; Penicillins; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Rats; Reproducibility of Results; Tazobactam | 2002 |
Jet-black eschar.
Topics: Anti-Bacterial Agents; Diagnosis, Differential; Drug Therapy, Combination; Ecthyma; Female; Gentamicins; Humans; Infant; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections | 2002 |
Pharmacodynamic profiling of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis.
Topics: Adult; Aged; Aged, 80 and over; Area Under Curve; Biological Availability; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Microbial Sensitivity Tests; Middle Aged; Monte Carlo Method; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Severity of Illness Index; Tazobactam; Treatment Outcome | 2002 |
Pseudomonas aeruginosa sacroiliitis and osteomyelitis of pelvic bones after radical prostatectomy.
Topics: Aged; Anti-Bacterial Agents; Ceftazidime; Humans; Male; Osteomyelitis; Pelvic Bones; Penicillins; Piperacillin; Postoperative Complications; Prostatectomy; Pseudomonas aeruginosa; Pseudomonas Infections; Sacroiliac Joint; Spondylitis | 2002 |
A case of recurrent acute generalized exanthematous pustulosis due to beta-lactam antibiotics: a case report.
Topics: Acute Disease; Anti-Bacterial Agents; Bacteremia; Ceftazidime; Diabetes Mellitus; Diagnosis, Differential; Exanthema; Hepatitis, Alcoholic; Humans; Male; Meropenem; Middle Aged; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Recurrence; Thienamycins | 2003 |
Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents.
Topics: Adult; Anti-Bacterial Agents; Ceftazidime; Ciprofloxacin; Colistin; Cystic Fibrosis; Drug Resistance, Bacterial; Gentamicins; Humans; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 2003 |
Pharmacodynamics of piperacillin in severely ill patients evaluated by using a PK/PD model.
Topics: Colony Count, Microbial; Critical Illness; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Models, Biological; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Soft Tissue Infections; Staphylococcal Infections; Staphylococcus aureus | 2003 |
In vitro activity of combination therapy with cefepime, piperacillin-tazobactam, or meropenem with ciprofloxacin against multidrug-resistant Pseudomonas aeruginosa strains.
Topics: Anti-Bacterial Agents; Cefepime; Cephalosporins; Drug Interactions; Drug Resistance, Multiple; Drug Therapy, Combination; Humans; Lactams; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2003 |
Piperacillin and gentamicin suppress Pseudomonas aeruginosa pyoderma acuta complicated by diabetes mellitus.
Topics: Diabetes Mellitus; Drug Combinations; Female; Gentamicins; Humans; Middle Aged; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Pyoderma | 2004 |
[Antimicrobial susceptibility of Pseudomonas aeruginosa isolated at Kochi Municipal Central Hospital in the last 3 years].
Topics: Amikacin; Anti-Bacterial Agents; Ceftazidime; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins; Tobramycin | 2004 |
[Investigation of the in-vitro effectiveness of ertapenem against Pseudomonas aeruginosa strains isolated from intensive care unit patients].
Topics: Anti-Bacterial Agents; beta-Lactams; Drug Resistance, Multiple, Bacterial; Ertapenem; Humans; Imipenem; Intensive Care Units; Lactams; Meropenem; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2004 |
Stable antimicrobial susceptibility rates for clinical isolates of Pseudomonas aeruginosa from the 2001-2003 tracking resistance in the United States today surveillance studies.
Topics: beta-Lactams; Ceftazidime; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Fluoroquinolones; Gatifloxacin; Gentamicins; Humans; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; United States | 2005 |
A comparison of intravitreal piperacillin/tazobactam with ceftazidime in experimental Pseudomonas aeruginosa endophthalmitis.
Topics: Animals; Anti-Bacterial Agents; Ceftazidime; Colony Count, Microbial; Drug Therapy, Combination; Endophthalmitis; Enzyme Inhibitors; Eye Infections, Bacterial; Female; Injections; Male; Penicillanic Acid; Piperacillin; Pseudomonas Infections; Rabbits; Retina; Tazobactam; Treatment Outcome; Vitreous Body | 2005 |
The efficacy of piperacillin/tazobactam in experimental Pseudomonas aeruginosa endophthalmitis: a histopathological and microbiological evaluation.
Topics: Animals; Anti-Bacterial Agents; beta-Lactamase Inhibitors; Colony Count, Microbial; Disease Models, Animal; Drug Therapy, Combination; Endophthalmitis; Eye Infections, Bacterial; Female; Male; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Tazobactam; Treatment Outcome; Vitreous Body | 2005 |
Pseudomonal sepsis with subcutaneous nodules in an HIV-infected individual with high CD4 counts.
Topics: Anti-Bacterial Agents; Anti-HIV Agents; Antiretroviral Therapy, Highly Active; CD4-Positive T-Lymphocytes; Gentamicins; Glucocorticoids; HIV Infections; Humans; Lymphocyte Count; Male; Middle Aged; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Pulmonary Disease, Chronic Obstructive; Respiration, Artificial; Sepsis; Skin Diseases; Tazobactam; Treatment Outcome | 2005 |
Plasma concentrations might lead to overestimation of target site activity of piperacillin in patients with sepsis.
Topics: Aged; Anti-Bacterial Agents; Humans; Microbial Sensitivity Tests; Middle Aged; Models, Biological; Organ Specificity; Piperacillin; Pseudomonas Infections; Sepsis; Staphylococcal Infections; Tissue Distribution | 2005 |
Pharmacodynamic modeling of beta-lactam antibiotics for the empiric treatment of secondary peritonitis: a report from the OPTAMA program.
Topics: Anti-Bacterial Agents; beta-Lactams; Cilastatin; Cilastatin, Imipenem Drug Combination; Drug Combinations; Humans; Imipenem; Meropenem; Microbial Sensitivity Tests; Models, Biological; Monte Carlo Method; Penicillanic Acid; Peritonitis; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 2005 |
Piperacillin/tazobactam in treatment of brain abscess.
Topics: Anti-Bacterial Agents; Basal Ganglia; Brain Abscess; Humans; Male; Middle Aged; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Radiography; Tazobactam; Treatment Outcome | 2006 |
Use of in vitro critical inhibitory concentration, a novel approach to predict in vivo synergistic bactericidal effect of combined amikacin and piperacillin against Pseudomonas aeruginosa in a systemic rat infection model.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Area Under Curve; Drug Synergism; Half-Life; Male; Microbial Sensitivity Tests; Penicillins; Piperacillin; Predictive Value of Tests; Pseudomonas aeruginosa; Pseudomonas Infections; Rats; Rats, Sprague-Dawley; Survival Analysis | 2006 |
Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; APACHE; beta-Lactams; Cohort Studies; Critical Illness; Cross Infection; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Male; Microbial Sensitivity Tests; Middle Aged; Models, Biological; Monte Carlo Method; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas Infections; Retrospective Studies | 2007 |
Appropriate comparators for alternate dosing strategies.
Topics: Aminoglycosides; Anti-Bacterial Agents; Cross Infection; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Infusions, Intravenous; Male; Monte Carlo Method; Penicillanic Acid; Piperacillin; Pneumonia, Bacterial; Prospective Studies; Pseudomonas aeruginosa; Pseudomonas Infections; Randomized Controlled Trials as Topic; Risk Assessment; Tazobactam; Treatment Outcome | 2007 |
[The frequency of PER-1 type extended spectrum beta-lactamases in nosocomial isolates of Pseudomonas aeruginosa].
Topics: Anti-Bacterial Agents; beta-Lactamases; Cross Infection; Drug Resistance, Multiple, Bacterial; Electrophoresis, Gel, Pulsed-Field; Humans; Imipenem; Meropenem; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Polymerase Chain Reaction; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins; Tobramycin | 2007 |
Molecular epidemiology of clinical Pseudomonas aeruginosa isolates carrying IMP-1 metallo-beta-lactamase gene in a University Hospital in Turkey.
Topics: Anti-Bacterial Agents; Aztreonam; beta-Lactamases; Drug Resistance, Multiple, Bacterial; Genes, Bacterial; Hospitals, University; Humans; Imipenem; Integrons; Microbial Sensitivity Tests; Molecular Epidemiology; Molecular Sequence Data; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Plasmids; Polymerase Chain Reaction; Pseudomonas aeruginosa; Pseudomonas Infections; Turkey | 2007 |
Optimal dosing of piperacillin-tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion?
Topics: Anti-Bacterial Agents; Computer Simulation; Drug Administration Schedule; Drug Resistance, Bacterial; Hospitals; Humans; Infusions, Intravenous; Microbial Sensitivity Tests; Monte Carlo Method; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Time Factors | 2007 |
The antimicrobial peptide tachyplesin III coated alone and in combination with intraperitoneal piperacillin-tazobactam prevents ureteral stent Pseudomonas infection in a rat subcutaneous pouch model.
Topics: Animals; Anti-Bacterial Agents; Antimicrobial Cationic Peptides; Bacterial Adhesion; Biofilms; Colony Count, Microbial; Disease Models, Animal; DNA-Binding Proteins; Drug-Eluting Stents; In Vitro Techniques; Male; Penicillanic Acid; Peptides, Cyclic; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Rats; Rats, Wistar; Ureteral Diseases | 2007 |
Piperacillin/tazobactam-heteroresistant Pseudomonas aeruginosa from urinary infection, successfully treated by piperacillin/tazobactam.
Topics: Adult; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combination; Humans; Male; Penicillanic Acid; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam; Urinary Tract Infections | 2008 |
Outcomes of bacteremia due to Pseudomonas aeruginosa with reduced susceptibility to piperacillin-tazobactam: implications on the appropriateness of the resistance breakpoint.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteremia; Cohort Studies; Drug Resistance, Bacterial; Female; Hospital Mortality; Humans; Male; Microbial Sensitivity Tests; Middle Aged; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas aeruginosa; Pseudomonas Infections; Treatment Outcome | 2008 |
Adverse reactions to piperacillin in cystic fibrosis.
Topics: Adult; Cystic Fibrosis; Female; Fever; Humans; Male; Piperacillin; Pseudomonas Infections | 1984 |
Adverse reactions to piperacillin in patients with cystic fibrosis.
Topics: Adolescent; Adult; Child; Cystic Fibrosis; Female; Humans; Male; Piperacillin; Pseudomonas Infections | 1984 |
Clinical evaluation of piperacillin with observations on penetrability into cerebrospinal fluid.
Topics: Haemophilus Infections; Humans; Klebsiella Infections; Meningitis; Penicillins; Piperacillin; Pneumonia; Pneumonia, Pneumococcal; Pseudomonas Infections | 1981 |
Sepsis associated with urinary tract infection. Antibiotic treatment with piperacillin.
Topics: Adult; Bacterial Infections; Enterobacteriaceae Infections; Female; Humans; Male; Middle Aged; Penicillins; Piperacillin; Pseudomonas Infections; Shock, Septic; Urinary Tract Infections | 1982 |
[Protective effect of Pseudomonas-specific immunoglobulin from the rabbit and of active immunization in experimental Pseudomonas sepsis in mice].
Topics: Animals; Antibodies, Bacterial; Cyclophosphamide; Immune Tolerance; Immunization; Immunization, Passive; Mice; Penicillins; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Rabbits; Sepsis | 1982 |
[Therapy of "malignant otitis externa"].
Topics: Aminoglycosides; Diabetes Complications; Diabetes Mellitus; Humans; Hyperbaric Oxygenation; Otitis Externa; Penicillins; Piperacillin; Pseudomonas Infections; Tobramycin | 1983 |
[Studies on the combination action of sisomicin, gentamicin and piperacillin, cefmetazole against Pseudomonas aeruginosa and Serratia marcescens].
Topics: Animals; Cefmetazole; Cephalosporins; Cephamycins; Drug Evaluation, Preclinical; Drug Synergism; Gentamicins; Male; Mice; Penicillin Resistance; Penicillins; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Serratia marcescens; Sisomicin | 1983 |
Piperacillin therapy for Pseudomonas infections.
Topics: Adolescent; Adult; Aged; Child; Child, Preschool; Drug Evaluation; Female; Humans; Kidney Diseases; Leukopenia; Male; Middle Aged; Penicillin Resistance; Penicillins; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Recurrence; Time Factors; Urinary Tract Infections | 1983 |
Activities of new beta-lactam antibiotics against isolates of Pseudomonas aeruginosa from patients with cystic fibrosis.
Topics: Anti-Bacterial Agents; beta-Lactams; Carbenicillin; Cefoperazone; Cefotaxime; Ceftazidime; Cephalosporins; Cystic Fibrosis; Imipenem; Penicillins; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections | 1981 |
Allergy to semisynthetic penicillins in cystic fibrosis.
Topics: Adolescent; Adult; Benzeneacetamides; Carbenicillin; Child; Cystic Fibrosis; Drug Hypersensitivity; Female; Humans; Intradermal Tests; Male; Penicillanic Acid; Penicillin G; Penicillins; Piperacillin; Polylysine; Pseudomonas Infections; Radioallergosorbent Test; Ticarcillin | 1984 |
Ceftazidime alone and in combination in patients with cystic fibrosis: lack of efficacy in treatment of severe respiratory infections caused by Pseudomonas cepacia.
Topics: Adolescent; Ceftazidime; Cephalosporins; Cystic Fibrosis; Drug Combinations; Drug Therapy, Combination; Female; Humans; Male; Piperacillin; Pseudomonas Infections; Respiratory Tract Infections; Sulfamethoxazole; Tobramycin; Trimethoprim; Trimethoprim, Sulfamethoxazole Drug Combination | 1983 |
Fosfomycin, piperacillin, azlocillin. Correlation between therapeutic response of mice infected with Pseudomonas aeruginosa and in vitro data.
Topics: Animals; Anti-Bacterial Agents; Azlocillin; Fosfomycin; Kinetics; Mice; Microbial Sensitivity Tests; Models, Biological; Penicillins; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections | 1984 |
Use of piperacillin, a semisynthetic penicillin, in the therapy of acute exacerbations of pulmonary disease in patients with cystic fibrosis.
Topics: Adolescent; Adult; Alcaligenes; Child; Cystic Fibrosis; Female; Humans; Kinetics; Lung Diseases; Male; Penicillins; Piperacillin; Pseudomonas Infections | 1980 |
Malignant external otitis due to Pseudomonas aeruginosa in childhood.
Topics: Child; Humans; Male; Otitis Externa; Penicillins; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections | 1980 |
Piperacillin treatment of urinary infections.
Topics: Adult; Aged; Enterobacter; Enterobacteriaceae Infections; Escherichia coli Infections; Female; Humans; Injections, Intravenous; Klebsiella Infections; Male; Middle Aged; Penicillins; Piperacillin; Proteus Infections; Pseudomonas Infections; Urinary Tract Infections | 1981 |
[Piperacillin, a new penicillin].
Topics: Drug Tolerance; Humans; Penicillin Resistance; Penicillins; Peritonitis; Piperacillin; Pseudomonas Infections; Tissue Distribution | 1981 |
Antibiotic treatment of chronic Pseudomonas aeruginosa infection in cystic fibrosis patients.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Azlocillin; Carbenicillin; Child; Child, Preschool; Chronic Disease; Cystic Fibrosis; Humans; Microbial Sensitivity Tests; Penicillins; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections | 1981 |
[Laboratory and clinical studies on cefsulodin (author's transl)].
Topics: Adult; Aged; Cefsulodin; Cephalosporins; Cystitis; Drug Evaluation; Female; Gentamicins; Humans; Male; Middle Aged; Penicillin Resistance; Penicillins; Piperacillin; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections | 1981 |
Chemotherapy against Pseudomonas aeruginosa in cystic fibrosis. A study of carbenicillin, azlocillin or piperacillin in combination with tobramycin.
Topics: Anti-Bacterial Agents; Azlocillin; Carbenicillin; Cystic Fibrosis; Drug Therapy, Combination; Humans; Penicillins; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Recurrence; Tobramycin | 1982 |
Moxalactam plus piperacillin versus moxalactam plus amikacin in febrile granulocytopenic patients.
Topics: Adolescent; Adult; Aged; Agranulocytosis; Amikacin; Bacteria, Anaerobic; Bacterial Infections; Child; Drug Evaluation; Drug Therapy, Combination; Enterobacteriaceae Infections; Female; Fever; Gram-Positive Bacteria; Humans; Infusions, Parenteral; Kanamycin; Male; Microbial Sensitivity Tests; Middle Aged; Moxalactam; Piperacillin; Pseudomonas Infections; Random Allocation; Staphylococcal Infections | 1984 |
Comparative efficacies of piperacillin, azlocillin, ticarcillin, aztreonam, and tobramycin against experimental Pseudomonas aeruginosa pneumonia.
Topics: Animals; Anti-Bacterial Agents; Azlocillin; Aztreonam; Guinea Pigs; Penicillins; Piperacillin; Pneumonia; Pseudomonas Infections; Ticarcillin; Tobramycin | 1984 |
In vitro activities of aztreonam, piperacillin, and ticarcillin combined with amikacin against amikacin-resistant Pseudomonas aeruginosa and P. cepacia isolates from children with cystic fibrosis.
Topics: Amikacin; Anti-Bacterial Agents; Aztreonam; Child; Cystic Fibrosis; Drug Therapy, Combination; Humans; Kanamycin; Penicillin Resistance; Piperacillin; Pseudomonas Infections; Ticarcillin | 1984 |
Piperacillin - another ureidopenicillin.
Topics: Drug Evaluation; Humans; Kinetics; Piperacillin; Pseudomonas Infections | 1983 |
Development of antibiotic resistance in Pseudomonas aeruginosa during two decades of antipseudomonal treatment at the Danish CF Center.
Topics: Anti-Bacterial Agents; beta-Lactamases; Carbenicillin; Ceftazidime; Ciprofloxacin; Cystic Fibrosis; Denmark; Drug Resistance, Microbial; Drug Therapy, Combination; Humans; Microbial Sensitivity Tests; Piperacillin; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Tobramycin | 1994 |
A reminder: piperacillin/tazobactam is not for Pseudomonas.
Topics: Adult; Drug Therapy, Combination; Humans; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pseudomonas Infections | 1994 |
Subcutaneous nodules as a dermatologic manifestation of bacteremia due to Pseudomonas aeruginosa.
Topics: Aged; Ceftazidime; Female; Gentamicins; Humans; Male; Middle Aged; Piperacillin; Pseudomonas Infections; Skin | 1994 |
[Prevention and antibiotic treatment of Pseudomonas aeruginosa septicemia].
Topics: Adolescent; Adult; Aged; Ampicillin Resistance; Bacteremia; Female; Humans; Male; Middle Aged; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections | 1993 |
[In vivo effect of growth-inhibitor produced by Pseudomonas aeruginosa isolates and anti-pseudomonal drugs on model infection due to Pseudomonas aeruginosa].
Topics: Animals; Anti-Bacterial Agents; Ceftazidime; Disease Models, Animal; Drug Resistance, Microbial; Growth Inhibitors; Male; Mice; Mice, Inbred ICR; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Sisomicin | 1993 |
Community-acquired Pseudomonas aeruginosa infection in an infant.
Topics: Anti-Bacterial Agents; Bacteremia; Community-Acquired Infections; Gentamicins; Humans; Infant; Kwashiorkor; Male; Penicillins; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections | 1996 |
The use of aztreonam as an alternate therapy for multi-resistant Pseudomonas aeruginosa.
Topics: Aminoglycosides; Aztreonam; Burns; Drug Resistance, Microbial; Drug Resistance, Multiple; Drug Therapy, Combination; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; Monobactams; Penicillins; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Retrospective Studies; Treatment Outcome; Wound Infection | 1997 |
Piperacillin-induced seizures.
Topics: Antimetabolites, Antineoplastic; Burkitt Lymphoma; Child; Humans; Male; Mercaptopurine; Methotrexate; Piperacillin; Pseudomonas Infections; Seizures; Sepsis; Staphylococcal Infections | 1997 |
Study quantifies impact of resistant Pseudomonas on outcomes.
Topics: Anti-Bacterial Agents; Boston; Ceftazidime; Ciprofloxacin; Drug Resistance, Microbial; Hospitalization; Humans; Imipenem; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections | 1999 |
Treatment of experimental pneumonia in rats caused by a PER-1 extended-spectrum beta-lactamase-producing strain of Pseudomonas aeruginosa.
Topics: Amikacin; Animals; Anti-Bacterial Agents; beta-Lactamases; Cefepime; Cephalosporins; Colony Count, Microbial; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Imipenem; Lung; Male; Microbial Sensitivity Tests; Penicillanic Acid; Piperacillin; Piperacillin, Tazobactam Drug Combination; Pneumonia, Bacterial; Pseudomonas aeruginosa; Pseudomonas Infections; Rats; Rats, Wistar | 1999 |
In-vitro effects of a combination of antipseudomonal antibiotics against multi-drug resistant Pseudomonas aeruginosa.
Topics: Amikacin; Anti-Bacterial Agents; Aztreonam; Ceftazidime; Drug Combinations; Drug Resistance, Microbial; Drug Resistance, Multiple; Humans; Meropenem; Microbial Sensitivity Tests; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Thienamycins | 1999 |
Acute tubulointerstitial nephritis following intravenous immunoglobulin therapy in a male infant with minimal-change nephrotic syndrome.
Topics: Acute Disease; Agammaglobulinemia; beta 2-Microglobulin; Biomarkers; Biopsy; Child, Preschool; Combined Modality Therapy; Drug Hypersensitivity; Humans; Immunization, Passive; Immunoglobulins, Intravenous; Immunosuppressive Agents; Kidney; Male; Nephritis, Interstitial; Nephrotic Syndrome; Penicillins; Piperacillin; Prednisolone; Pseudomonas Infections; Recurrence; Urinary Tract Infections | 1999 |
Activity of piperacillin/tazobactam in combination with amikacin, ciprofloxacin, and trovafloxacin against Pseudomonas aeruginosa by time-kill.
Topics: Amikacin; Anti-Bacterial Agents; Anti-Infective Agents; Chi-Square Distribution; Ciprofloxacin; Colony Count, Microbial; Drug Resistance, Microbial; Drug Synergism; Drug Therapy, Combination; Enzyme Inhibitors; Fluoroquinolones; Humans; Naphthyridines; Penicillanic Acid; Penicillins; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Tazobactam | 2000 |
Eradication of a resistant Pseudomonas aeruginosa strain after a cluster of infections in a hematology/oncology unit.
Topics: Bacteremia; Cross Infection; Drug Resistance, Multiple; Enzyme Inhibitors; Hospitals, General; Humans; Infection Control; Intensive Care Units; Microbial Sensitivity Tests; Oncology Service, Hospital; Penicillanic Acid; Penicillin Resistance; Penicillins; Piperacillin; Pneumonia; Pseudomonas aeruginosa; Pseudomonas Infections; Sanitary Engineering; Scotland; Species Specificity; Sputum; Tazobactam | 2000 |
Risk factors for piperacillin-tazobactam-resistant Pseudomonas aeruginosa among hospitalized patients.
Topics: Adult; Case-Control Studies; Cross Infection; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Penicillanic Acid; Penicillin Resistance; Penicillins; Piperacillin; Pseudomonas Infections; Regression Analysis; Risk Factors; Tazobactam | 2002 |
[Clinico-bacteriological evaluation of the effectiveness of piperacillin in suppurative-inflammatory diseases of the lungs and pleura].
Topics: Culture Media; Drug Resistance, Microbial; Empyema, Pleural; Enterobacteriaceae; Enterobacteriaceae Infections; Humans; In Vitro Techniques; Microbial Sensitivity Tests; Piperacillin; Pleurisy; Pneumonia, Staphylococcal; Pseudomonas; Pseudomonas Infections; Staphylococcus aureus | 1992 |
[Common pathogens in burn infection and changes in their drug sensitivity].
Topics: Amikacin; Burns; Ciprofloxacin; Female; Humans; Male; Microbial Sensitivity Tests; Piperacillin; Proteus; Proteus Infections; Pseudomonas aeruginosa; Pseudomonas Infections; Staphylococcal Infections; Staphylococcus aureus | 1991 |
Cure of persistent Pseudomonas peritonitis after prolonged antibiotic administration in CAPD patients.
Topics: Adult; Aged; Ceftazidime; Drug Therapy, Combination; Gentamicins; Humans; Male; Peritoneal Dialysis, Continuous Ambulatory; Peritonitis; Piperacillin; Pseudomonas Infections; Time Factors | 1991 |
[Changes in resistance of Pseudomonas aeruginosa to beta-lactams in a general intensive care unit over a three-year period. Role of piperacillin].
Topics: Cefsulodin; Ceftazidime; Cross Infection; Drug Resistance, Microbial; Female; Humans; Imipenem; Intensive Care Units; Male; Middle Aged; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Ticarcillin | 1991 |
In vivo inactivation of tobramycin by piperacillin.
Topics: Drug Interactions; Female; Half-Life; Humans; Kidney Failure, Chronic; Male; Middle Aged; Piperacillin; Pseudomonas Infections; Tobramycin | 1991 |
[Studies of dosing regimens and combination effects of aminoglycosides and beta-lactam in an experimental Pseudomonas aeruginosa infection in mice].
Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Gentamicins; Mice; Mice, Inbred ICR; Piperacillin; Pseudomonas Infections | 1991 |
[Detection of inducible beta-lactamase in sputum--clinical studies on Pseudomonas respiratory infection].
Topics: beta-Lactamases; Cefmetazole; Enzyme Induction; Humans; Piperacillin; Pseudomonas Infections; Respiratory Tract Infections; Sputum | 1989 |
Antipseudomonal activity of simulated infusions of gentamicin alone or with piperacillin assessed by serum bactericidal rate and area under the killing curve.
Topics: Blood Bactericidal Activity; Gentamicins; Humans; In Vitro Techniques; Infusions, Parenteral; Microbial Sensitivity Tests; Models, Biological; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections | 1989 |
Synergy of ciprofloxacin and azlocillin in vitro and in a neutropenic mouse model of infection.
Topics: Animals; Azlocillin; Bacteria; Carbenicillin; Ciprofloxacin; Drug Synergism; Drug Therapy, Combination; Enterobacteriaceae; Gentamicins; Humans; Listeria monocytogenes; Male; Mice; Neisseriaceae; Neutropenia; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Quinolines; Staphylococcus aureus; Streptococcus; Ticarcillin | 1986 |
Combined imipenem/cilastatin and tobramycin therapy of multiresistant Pseudomonas aeruginosa in cystic fibrosis.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Bronchopneumonia; Child; Chronic Disease; Cilastatin; Cilastatin, Imipenem Drug Combination; Cyclopropanes; Cystic Fibrosis; Drug Combinations; Drug Synergism; Drug Therapy, Combination; Female; Humans; Imipenem; Kinetics; Male; Microbial Sensitivity Tests; Penicillin Resistance; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Sputum; Thienamycins; Tobramycin | 1987 |
Selection of resistance by piperacillin during Pseudomonas aeruginosa endocarditis.
Topics: beta-Lactamases; Endocarditis, Bacterial; Humans; Male; Middle Aged; Penicillin Resistance; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections | 1988 |
[Synergistic activity of isepamicin and beta-lactam antibiotics against Pseudomonas aeruginosa in vitro and in vivo].
Topics: Animals; Anti-Bacterial Agents; Cefotaxime; Drug Synergism; Drug Therapy, Combination; Gentamicins; Male; Mice; Mice, Inbred ICR; Peritonitis; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Respiratory Tract Infections | 1988 |
Microbial pharmacodynamics of piperacillin in neutropenic mice of systematic infection due to Pseudomonas aeruginosa.
Topics: Agranulocytosis; Animals; Drug Administration Schedule; Mathematics; Mice; Models, Theoretical; Neutropenia; Piperacillin; Pseudomonas Infections | 1988 |
Impact of dosage regimens on the efficacy of piperacillin against Pseudomonas aeruginosa in neutropenic mice.
Topics: Agranulocytosis; Animals; Female; Mice; Mice, Inbred A; Mice, Inbred ICR; Neutropenia; Piperacillin; Pseudomonas Infections; Ticarcillin | 1988 |
Failure of therapy in pseudomonas endocarditis: selection of resistant mutants.
Topics: Adult; beta-Lactamases; Electrophoresis, Agar Gel; Endocarditis, Bacterial; Female; Humans; Isoelectric Focusing; Male; Microbial Sensitivity Tests; Mutation; Penicillin Resistance; Piperacillin; Pseudomonas Infections; Tobramycin | 1986 |
Synergistic activity of apalcillin and gentamicin in a combination therapy in experimental Pseudomonas bacteraemia of neutropenic mice.
Topics: Ampicillin; Animals; Drug Synergism; Drug Therapy, Combination; Female; Gentamicins; Mice; Microbial Sensitivity Tests; Naphthyridines; Neutropenia; Piperacillin; Pseudomonas Infections; Sepsis | 1986 |
Pseudomonas cepacia endophthalmitis.
Topics: Aged; Cataract Extraction; Cefotaxime; Endophthalmitis; Gentamicins; Glaucoma; Humans; Iritis; Laser Therapy; Lenses, Intraocular; Male; Penicillin Resistance; Piperacillin; Pseudomonas; Pseudomonas Infections; Recurrence; Surgical Wound Infection; Trabecular Meshwork; Vitreous Body | 1985 |
Comparative activities of piperacillin, ceftazidime, and amikacin, alone and in all possible combinations, against experimental Pseudomonas aeruginosa infections in neutropenic rats.
Topics: Amikacin; Animals; Anti-Bacterial Agents; Ceftazidime; Drug Therapy, Combination; Female; Neutropenia; Penicillin Resistance; Peritonitis; Piperacillin; Pseudomonas Infections; Rats; Rats, Inbred Strains; Sepsis | 1985 |
Synergistic action of silver sulfadiazine and sodium piperacillin on resistant Pseudomonas aeruginosa in vitro and in experimental burn wound infections.
Topics: Administration, Topical; Animals; Burns; Culture Media; Drug Synergism; Female; Mice; Penicillin Resistance; Piperacillin; Pseudomonas aeruginosa; Pseudomonas Infections; Rats; Rats, Inbred Strains; Silver Sulfadiazine; Sulfadiazine; Wound Infection | 1985 |
Malignant external otitis in a diabetic adolescent.
Topics: Adult; Amikacin; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Humans; Male; Otitis Externa; Piperacillin; Pseudomonas Infections | 1986 |
Neutropenia associated with mezlocillin and piperacillin.
Topics: Adult; Agranulocytosis; Humans; Male; Mezlocillin; Neutropenia; Piperacillin; Pneumonia; Pseudomonas Infections | 1985 |
Adverse reactions to piperacillin in adults with cystic fibrosis.
Topics: Adult; Azlocillin; Carbenicillin; Cystic Fibrosis; Female; Fever; Humans; Male; Piperacillin; Pseudomonas Infections; Respiratory Tract Infections | 1985 |
Prolonged elimination of piperacillin in a patient with renal and liver failure.
Topics: Adult; Female; Half-Life; Humans; Kidney Failure, Chronic; Leukemia; Liver Diseases; Piperacillin; Pseudomonas Infections | 1985 |
Purulent meningitis due to Pseudomonas aeruginosa successfully treated with colistin and piperacillin.
Topics: Colistin; Drug Therapy, Combination; Humans; Male; Meningitis; Middle Aged; Piperacillin; Pseudomonas Infections | 1985 |